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CHAPTER 1
Introduction
Depression has been a topic of research for many years. All the evidence indi-
cates that causation of depression is multifactorial; the disorder has many cau-
ses, with an amalgam of genetic make-up, early environmental, biological fac-
tors, and recent social stresses (Paykel, 1989). However, scientific research has
not yet reached definite conclusions on the etiology, pathogenesis, course or
treatment of this complex disorder (Keller, 1989). "
It is now widely recognized that in some patients biological factors play an
important role (Klerman, 1984). This view is supported by several clinical
observations, i.e. the iatrogenetic induction of depression by some medications
and by exogenous hormones, the therapeutic response to antidepressant drugs,
electroconvulsive therapy, manipulations of sleep, and light therapy.
Furthermore, in different fields of research some support for the existence of
biological disturbances has been obtained, such as in studies of monoamine
neurotransmission, genetic factors, biological rhythms, and sleep physiology.
Nevertheless, the precise biological factors concerning the etiology, pathogene-
sis and recovery of depression remain unknown. It seems very unlikely that
there is just one biological factor or disturbance involved.
During the past decades the role of sleep dysregulation in depression has
aroused great interest in the search for biological abnormalities in depression
(Gillin and Borbely, 1985). The therapeutic benefits of non-pharmacological
sleep manipulations in depressives suggest that sleep changes are of importance
for the recovery of depression. Drugs with antidepressant properties bring
about remarkable changes in sleep. The major topic of this thesis is the rela-
tionship between changes in sleep and in clinical state in depressed patients
during treatment with an antidepressant drug. Four studies are presented con-
cerning the effects of antidepressant drugs on sleep in depressives and their
possible significance for the amelioration of depressive symptomatology.
Before the studies are presented I will describe the empirical and conceptual
backgrounds of the effects of antidepressant drugs on sleep in this introductory
chapter.
1.1. SLEEP AND DEPRESSION
Sleep disturbances have been considered as cardinal symptoms of depression
for as long as this disorder has been described. Clinical descriptions going back
as far as the ancient Greeks have included disturbed sleep as part of the syndro-
me of melancholia (Jackson, 1986). According to contemporary diagnostic cri-
teria for mental disorders (DSM-III-R; APA, 1987) severe sleep complaints form
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a prominent part of the symptomatology of depression'. Approximately 90 %
of the patients suffering from a depression report complaints of initiating and
maintaining sleep as well as early awakening and remaining awake (ISCD, 1990).
So profound is the insomnia of these patients that many experience the distur-
bance primarily as a sleep disorder (Goodwin and Jamison, 1990).
The systematic examination of sleep in depressed patients began in the 1950s
almost immediately after the introduction of modern polygraphic techniques
for electrophysiological recording of sleep-related events (see review by Gillin,
1983a), i.e. by means of electro-encephalography (EEG), electro-oculography
(EOG) and electro-myography (EMG). Sleep disturbances of depressives have
been registrated objectively by means of polysomnography (EEG, EOG and
EMG), for many years now (see reviews by Gillin et al., 1984; Reynolds and
Kupfer, 1987). Compared to healthy controls, subjects with a depression dis-
play: prolonged sleep latency, frequent awakenings, early sleep termination,
increase of rapid eye movement sleep (REMS) in the first part of sleep, short
REMS latency, diminished production of non-REMS stages 3 and 4 (slow wave
sleep or SWS), and large variability in non-REMS-REMS cycle duration. None of
these changes appears to be pathognomonic of depression (Wehr, 1990).
Recently, an extensive review has appeared of the literature on sleep in psy-
chiatric disorders with an evaluation of the polysomnographic data by statisti-
cal meta-analysis (Benca et al., 1992; 177 studies concerning 7151 patients and
controls). A striking result was that depressive disorders differed significantly
from controls for the majority of the sleep variables. The median values of
REMS latency, total time asleep, SWS (minutes and percentage from total time
asleep) were lower, and REMS (percent) values higher, in depressive disorders
than in all other diagnostic categories. However, the statistical differences
between depressive disorders and other psychiatric categories were far less
obvious; no sleep variable reliably distinguished depressive disorders from
other psychiatric disorders. A shortened REMS latency, for example, also occur-
red in subjects with narcolepsy, and sometimes in schizophrenia, borderline
disorder, and eating disorders; reduction of SWS was seen in alcoholism and in-
somnia. The authors suggest that the sleep disturbances in depressive disorders
are more profound and widespread than in other diagnostic categories, but are
not specific for depression.
Because sleep disturbances are so strongly associated with the depressive
state, an obvious question is whether these disturbances play a role in the
pathogenesis and recovery of depression. It is now widely recognized that a
number of sleep manipulations ameliorate symptoms of depression (see reviews
by Gillin, 1983b; Leibenluft and Wehr, 1992). These include total and partial
' i.e. major depressive episode as (single or recurrent) episode of a major depression, or of a bipolar
disorder.
11
sleep deprivation, selective deprivation of REMS, and phase shifting of the sleep-
wake cycle. Total and partial sleep deprivation induce an immediate improve-
ment in about 60 % of depressed subjects, which is often reversed by recovery
sleep (i.e. subsequent sleep). The therapeutic effects of selective REMS depriva-
tion on depression occur in about 50 %. These effects have a slower onset (3
weeks) but last longer. If total sleep deprivation is combined with antidepres-
sant medication, which started on the day prior to the sleep deprivation, this
sometimes resulted in the absence of relapse after the recovery sleep (Elsenga
and Van den Hoofdakker, 1983; Kasper et al, 1990). It has also been reported
that the response to sleep deprivation has some predictive value for the respon-
se to regular antidepressant treatment (see for ref.: Leibenluft and Wehr 1992).
Another fact worth mentioning in this context is that antidepressant drugs
bring about remarkable changes in sleep polygraphic variables. This subject
will be discussed more extensively in the remainder of this chapter.
In summary, the reported findings that manipulations of sleep have clinical
benefits in some patients together with the influence of antidepressant drugs
upon sleep suggest that sleep changes are not merely epiphenomena of depres-
sion. Changes in sleep physiological processes might, therefore, be intimately
involved in the pathogenesis and recovery of depression (Gillin and Borbely,
1985; Van den Hoofdakker and Beersma, 1988; Wehr, 1990).
One way to elucidate the link between sleep and depression is to examine
whether the influence of antidepressant drugs on sleep is related to clinical
changes of depressives during treatment. For that purpose the remainder of this
chapter deals with a review concerning the effects of antidepressants on sleep
and their importance for the alleviation of depression. Four hypotheses about
sleep and depression will form the conceptual framework. The chapter ends
with a short description of the studies presented in the next chapters.
1.2. THE INFLUENCE OF ANTIDEPRESSANT
DRUGS ON SLEEP
Studies on the effects of antidepressant drugs (ADs) upon sleep polygraphic
variables in man are listed in Table 1.
The results of these studies can be subdivided in effects on REMS, on non-REMS
and on sleep continuity. The effects on REMS characteristics have been investi-
gated more frequently and systematically than those on the other sleep poly-
graphic variables. They will be summarized first.
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Table 1. Summary of the significant effects of antidepressant drugs (in alphabetical order) upon
REMS, REMS latency (REMSL), intermittent wakefulness (SO), non-REMS stages (SI and S2 = non-REMS
stages 1 and 2; SWS= slow wave sleep, non-RF,MS stages 3 & 4), sleep latency (SL), and total time
asleep (TTA) in healthy (H) and depressed (D) subjects. Dosage: 50 = one dose or a fixed dosage
schedule; 50-200 = increasing dosage schedule; 75;150 = two different dosages, one time.
Treatment: - = decrease in duration; 0 = no change in duration; + = increase in duration; # = becau-
se of almost completely abolished REMS no REMS latency detectable. Withdrawal: R = rebound
increase of REMS or rebound decrease of REMS latency; M = maintenance of treatment level or par-
tial return to pretreatment level. It should be noted that the different studies of this review are not
completely comparable. The studies may differ, among others, with respect to treatment duration,
dosage regimen, and subject characteristics. Moreover, the studies can differ concerning poly-
somnographic methods. Comparisons between the studies must, therefore, be made with caution.
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The majority of the ADs of all existing chemical classes (i.e. the various cyclic
compounds and monoarnine oxidase inhibitors) appears to have clear-cut influ-
ences on sleep of bo th healthy and depressed subjects: almost all suppress REMS
significantly, tolerance to this REMS suppression does not develop, REMS latency
time is increased, and a REMS rebound (an increase in REMS duration relative to
the pre-treatment level) can be observed once the drug is discontinued. Table 1
shows that no REMS suppression was reported in 6 out of 40 studies in depressi-
ves, and in 8 out of 33 studies in healthy controls. Only 3 ADs, i.e., amineptine
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(Bramanti et al, 1985; Di Perri et al, 1986), nefazodone (Sharpley et al., 1992),
and trimipramine (Wiegand et al., 1986) are reported to increase REMS.
The studies of the effects of ADs on sleep in depressives differ from those in
healthy subjects with respect to several important aspects. The majority of the
studies in healthy subjects focus on effects over periods encompassing only
very few days. Since it takes several weeks before the therapeutic effects of ADs
become apparent, the studies which deal only with the acute effects on sleep in
healthy subjects are considered irrelevant in this context and are excluded from
the following analysis. Figure 1 shows the results of the estimated long-term
changes, per AD, of REMS and REMS latency in depressives.
Figure 1. The estimated changes per AD of REMS durat ion and REMS latency in depressives. The rank
order of the various ADs is based on their degree of REMS suppression. The values per AD are based
on the means of the results of one or more studies in depressives (for references: see Table 1), and
are expressed relative to the pre-treatraent levels. The n u m b e r of studies used per AD is shown
between brackets.
* = because REMS was almost completely abolished, no REMS latency was detectable.
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The classical monoamine oxidase inhibitors (MAOIs; i.e. clorgyline, isocarboxa-
zid, pargyline, phenelzine and tranylcypromine) may completely abolish the
signs of REMS in the first 1-3 weeks of treatment. During continued medication
for up to 2 months their REMS suppressing effects remain (Akindele et al, 1970;
Wyatt et al., 1969; 1971). Upon discontinuation of these compounds REMS may
show a rebound of more than 250 % compared to baseline levels, persisting for
days or even weeks. In contrast to the classical MAOIs the new reversible selecti-
ve MAOIs (i.e. moclobemide and brofaromine) are reported to have a smaller
REMS suppressant effect (Monti et al., 1990; Nolen et al., 1993). From Fig. 1 it
can be seen that most of the various cyclic ADs suppress REMS and induce a
lenghthening of the REMS latency to varying degrees. Most of them already do
so after acute administration (see reviews by Chen, 1979; Scherschlicht et al.,
1982; Vogel et al., 1990; Van Bemmel, 1990; Havermans and Van Bemmel,
1991).
In contrast to studies of REMS changes, the effects of ADs on the duration of the
various stages of non-REMS and on sleep continuity (i.e. intermittent wakeful-
ness, sleep latency, total time asleep) have been investigated less systematically.
A general pattern in the effects on these sleep polygraphic variables in both
healthy subjects and depressives cannot yet be detected. Because of the afore-
mentioned differences between the studies in healthy and depressive subjects,
only the data on non-REMS and sleep continuity in depressives are summarized
in Figure 2.
Non-REMS stage 2 is reported to increase in 65 % of the studies, while 83 %
show no significant change in SWS duration. 65 % of the studies report no chan-
ge of sleep latency and 43 % no change of total time asleep.
While most ADs, of all existing chemical classes, influence REMS in a comparable
way, their effects on non-REMS and sleep continuity are much more variable.
Recently, it was reported in healthy subjects that the latter variability could be
associated with the chemical profile of ADs (Nicholson and Pascoe, 1991; Saletu
et al., 1991). The acute effects of ADs with mainly noradrenergic (NA) uptake
inhibition appear to induce sedation, whereas ADs with mainly serotonergic (5-
HT) uptake inhibition increase both nocturnal wakefulness and alertness during
the day. Inspired by these observations the effects of ADs with mainly 5-HT
uptake inhibition on sleep polygraphic variables of depressives were compared
wi th those of ADs wi th mainly NA uptake inhibition (Berger et al., 1986;
Kerkhofs et al., 1990; Kupfer et al., 1991). It was found that both 5-HT and NA
uptake inhibitors suppressed REMS. In contrast to the NA uptake inhibitors the
5-HT uptake inhibitors produced more sleep discontinuity by increasing wake-
fulness.
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Figure 2. Changes of non-REMS stages, sleep latency and total t ime asleep during treatment with
ADs, as reported in 23 studies in depressives (for references: sec Table 1). O o l y trie studies which
reported results of all the sleep variables involved are used in the figure, i.e. 3 studies are excluded.
The majority of the studies shows no significant changes in, the durat ion of the non-REMS stage 1,
sleep latency and total time asleep, but shows a significant increase of non-REMS stage 2. In only 4
out of 23 studies a change in SWS was found: three with a decrease and one with an increase.
SO = intermittent wakefulness; SI and S2 = non-REMS stages 1 and 2; sws = slow wave sleep (non-
REMS stages 3 & 4); SL = sleep latency; TTA = total t ime asleep.
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1.3. THE IMPORTANCE OF THE INFLUENCE
OF ADs ON SLEEP FOR THE ALLEVIA-
TION OF DEPRESSION
Drugs which alleviate depression appear to influence REMS variables rather con-
sistently, whereas their influence on non-REMS and sleep continuity variables is
much less evident and uniform. The question is whether changes in sleep poly-
graphic variables, during treatment with ADs, have clinical significance. • .,:
Only a minority of the studies on the effects of ADs on sleep in depressives has
focussed on the relationship between changes in sleep polygraphic variables
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and clinical response. The results of early reports suggest that in patients who
respond to classical MAOIs the clinical improvement coincides with the onset of
maximal REMS suppression (Wyatt et al., 1971; Dunleavy and Oswald, 1973). In
studies with the AD amitriptyline it was found that the depressive patients who
improved after 5 weeks showed a higher degree of REMS suppression at the start
of the treatment (Gillin et al., 1978; Kupfer et al., 1981). However, in a retro-
spective study over a 5-7-week treatment period with amitriptyline a relation-
ship between changes in REMS and clinical response could not be found
(Mendlewicz et al., 1991). Moreover, improvement of depression after 19 days
of treatment with the AD clomipramine did not correlate with the amount of
initial REMS reduction (Riemann and Berger, 1990).
A shortened baseline REMS latency has been proposed to be predictive of poor
treatment outcome (Kupfer et al., 1981). Rush et al. (1989) reported, however,
that a short pre-treatment REMS latency predicted a good treatment response in
depressed outpatients after a 6-week treatment with either amitriptyline or
desipramine. In contrast, Reynolds et al. (1991) reported that a prolonged base-
line REMS latency was significantly associated with clinical improvement in
elderly depressed patients treated with nortriptyline.
There are very few reports on the therapeutic significance of changes in non-
REMS or sleep continuity (Kupfer et al., 1978; Kupfer et al., 1982; Ware et al.,
1989). The differences in drug properties with respect to their impact on these
sleep polygraphic variables are, so far, not clearly related to antidepressant effi-
cacy (Mendelson, 1987). In the studies (Berger et al., 1986; Kerkhofs et al.,
1990; Kupfer et al., 1991), mentioned earlier, in which the effects of ADs with
mainly 5-HT inhibition were compared with those of drugs whith mainly NA
inhibition, no differences were found in therapeutic response, notwithstanding
their different effects on sleep continuity.
In summary, the clinical significance of the relationship between changes in
sleep polygraphic variables and changes in depressive symptomatology during
treatment with ADs is far from clear.
1.4. THEORETICAL APPROACHES
In this paragraph four hypotheses are reviewed, in which sleep physiology
plays a role in the pathogenesis of depression and the mechanisms underlying
the effects of antidepressive treatment.
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1.4.1. The REMS pressure hypothesis
The REMS pressure hypothesis is based on the assumption that strong initial and
sustained REMS suppression is the key mechanism underlying treatment respon-
se (Vogel et al., 1975; 1977; 1980). The origin of the interest in the role of REMS
abnormalities in psychopathology is closely related to the discovery of REMS
(Wehr and Sack, 1988). In the early 1950s Aserinsky and Kleitman (1953)
observed the periodic alternations of sleep with and sleep without the occur-
rence of rapid eye movements throughout the night. Awakenings induced
during REMS yielded accounts of dreams in 90 to 95 percent of the cases, and
those during non-REMS yielded reports of dreams in only 5 to 10 percent.
Furthermore, REMS deprivation appeared to lead to a REMS debt which was
compensated for during recovery sleep. These observations inspired intensive
research into the psychological and physiological functions of REMS (see
reviews by Dement, 1972; Hartmann, 1973).
The finding that most dreams are reported after awakening from REMS, coup-
led with the opinion (inspired by psychoanalytic theory) that dreaming repre-
sents an important mental function, led to the assumption that a shortage of
REMS would impair mental functioning, and could even lead to mental disorders
(Dement, 1960; Fisher and Dement, 1963; Snyder, 1963). Supposed similarities
between psychotic symptoms and dreams suggested that a psychosis was an
intrusion of dreams into wakefulness (Gillin and Wyatt, 1975). It was predicted
that REMS deprivation would induce psychotic symptoms, and indeed one sub-
ject developed psychotic symptoms while participating in a sleep deprivation
protocol (Kleitman, 1963). In all later studies, however, no psychopathology
was observed (Kales et al., 1964; Snyder, 1963; Mendelson, 1987).
At about that time, Snyder (1969) proposed the REMS deprivation hypothesis
of the pathogenesis of depression; a shortened REMS latency, in particular
observed in the severest phase of depression would result from prior depriva-
tion of REMS in the early phase of depression. Longitudinal data from later pha-
ses are not necessarily consistent with this (see for references: Gillin, 1983a).
Summarizing, today it seems unlikely that REMS deprivation has serious psy-
chopathological consequences. In fact, REMS deprivation may even be beneficial
for the treatment of depression. In the late 1960s, Vogel and his colleagues
reported that several lines of evidence were consistent with the hypothesis that
REMS plays an important role in the pathogenesis and the treatment of depres-
sion (summarized in: Vogel, 1975). Firstly, ADs produce substantial, persistent
suppression of REMS, much more than drugs without antidepressant properties;
secondly, electroconvulsive shock therapy has been reported to decrease REMS;
thirdly, reserpine, which induces depression, substantially increases REMS; and,
fourthly, prolonged REMS deprivation of animals produces behavioral changes
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opposite to the behavioral characteristics of human depression, i.e., REMS depri-
ved animals become hypersexual, hyperactive, and hyperphagic, while depres-
sed humans typically lose libido, display psychomotor retardation, and are
anorectic.
Several pilot tests of the hypothesis yielded promising results (Vogel, 1968;
Vogel and Traub, 1968a; 1968b; 1968c). Five out of nine patients improved sub-
stantially during REMS deprivation; one patient improved slightly.
Subsequently, a double-blind, cross-over study (Vogel et al., 1975) was con-
ducted in 34 patients with endogenous and 18 patients with reactive depression,
all hospitalized. REMS deprivation was applied to one group of depressives,
while another group was awakened from non-REMS with the same frequency.
After three weeks REMS deprivation was also applied to this latter group.
During selective sleep deprivation treatment each subject was awakened from
REMS or non-REMS on consecutive nights until the subject reached 30 awake-
nings per night or until six consecutive nights of selective sleep deprivation had
taken place, whichever came first. The subject then had a single night of unin-
terrupted sleep (recovery night) after which the same deprivation procedure
was repeated. The entire treatment lasted several weeks. Clinical improvement
occurred during REMS deprivation in about 50 % of the endogenously depres-
sed patients. The reactively depressed patients did not improve. During non-
REMS deprivation none of the patients showed improvement. Eleven patients
who had not responded to REMS deprivation received a treatment with imipra-
mine; only one improved sufficiently to be discharged.
The authors (Vogel et al , 1975) concluded that their results indicate that sub-
stantial REMS reduction is antidepressant and that the antidepressant mechanism
of ADs might reside in their capacity to reduce REMS substantially. From a fur-
ther analysis with the same data Vogel et al. (1977) reported a positive and sig-
nificant correlation between improvement of depression and REMS pressure.
This pressure was defined as the percentage of REMS in the first recovery night
devided by the mean REMS percentage of the last two baseline nights. In the aut-
hors" view this correlation indicates that REMS pressure is the manifestation of a
process mediating the antidepressant effects of REMS deprivation. The antide-
pressant effects of repeated REMS deprivations have not yet been replicated. The
complicated and laborious procedure required is probably the reason for this.
In 1990', Vogei et al. presented an extensive review of the literature on the influ-
ence of drugs on REMS in animals and humans, including subjects with endoge-
nous depression (from 1962 to 1989; 215 studies). The literature on the thera-
peutic efficacy of ADs is also included in that study. The authors reviewed the
REMS effects of amine precursors, antidepressants, antihistamines, antipsycho-
tics, barbiturates, benzodiazepines, other hypnotics, drugs affecting cholinergic
and noradrenergic neurotransmission, ethanol, lithium and narcotics. The REMS
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effects were evaluated with criteria derived from the properties of selective
REMS deprivation by arousals (so called: arousal-type REMS deprivation or AT-
RSD). Firstly, an initial reduction of REMS duration of more than 50% of the
pre-treatment level is required; secondly, this reduction of REMS must persist
for several weeks; and, thirdly, immediately upon cessation of the drug a REMS
rebound must occur.
The authors elaborately examined which drugs fulfill these properties of AT-
RSD. They found that drugs that produce AT-RSD also improve endogenous
depression. The influence of non-ADs on REMS proved never to fulfill the crite-
ria for AT-RSD. The antidepressant efficacy of drugs that produced AT-RSD
appeared not to be related to certain chemical classes. It was further concluded
that the dose threshold for antidepressant efficacy appeared to be the threshold
at which substantial REMS suppression is produced.
A few remarks should, however, be made. Firstly, not all ADs have been stu-
died sufficiently to be certain of their influence on REMS; secondly, although the
majority of efficacious ADs produced AT-RSD, not all did so (i.e. amineptine,
iprindole, trazodone, and trimipramine), which means that AT-RSD cannot be
the exclusive mechanism of action underlying drug induced improvement;
thirdly, in their evaluation Vogel et al. also included studies in animals and
non-depressed subjects; and, fourthly, most importantly, they could not find
studies in which the relationship between drug induced AT-RSD and antidepres-
sant effect was examined directly.
Recently, interesting data were obtained in an animal model for depression,
which could support the REMS pressure hypothesis (Adrien et al., 1991; Adrien,
1992). In this so-called learned helplessness model, rats are exposed to inesca-
pable electric footshocks which result in severe retardation in subsequent lear-
ning to escape or avoid shock in a different situation. During the initial period
after the induction of helplessness in rats transient sleep impairments of para-
doxical sleep (PS) were found, in particular shortened PS latencies and increased
PS amounts (Adrien et al., 1991). These changes are very similar to the sleep
abnormalities observed in depressed patients. Subsequently, in another study
(Adrien, 1992) it was observed that repetitive selective deprivation of PS could
abolish the behavioral deficits of the learned helplessness syndrome.
In summary, the therapeutic effect of REMS deprivation by arousals and the
effects of the majority of ADs upon REMS suggest that strong initial and sustai-
ned REMS suppression might be a central factor, without being the only factor
involved in the mechanisms underlying treatment response.
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1.4.2. The acetylcholine-rnonoaminergic balance model, and the
hypothesis of a common pathophysiological mechanism
underlying both REMS disturbance and depression
A second and related hypothesis to be mentioned in the context of this thesis is
based on the acetylcholine-rnonoaminergic (ACh-MA) balance model of sleep
cycle control in cats. It has been observed that neuronal activity in the medial
reticular nucleus in the pons increased during the transition from non-REMS to
REMS, while that in the locus coeruleus decreased. Acetylcholine (Ach) was sup-
posed to be the neurotransmitter of the first cell group and noradrenaline (NA)
that of the second (McCarley and Hobson, 1975). On the basis of several expe-
riments Hobson et al. (1975) proposed that the NA cells are auto-inhibitory and
also inhibit activity in the ACh system, whereas the Ach sytem is self-excitatory
and also stimulates the NA system. In this way, neuronal activity would alterna-
te between one cell group and the other. ACh activity promotes the occurrence
of REMS and NA activity suppresses REMS, and non-REMS-REMS cyclicity results.
Throughout the years, further animal experiments prompted the investigators
to modify the model drastically (Hobson et al., 1986). Firstly, a role was attri-
buted to the 5-HT activity in the suppression of REMS; secondly, wakefulness
was added as a third state, besides REMS and non-REMS; and, thirdly, it was con-
cluded that the two neurochemically distinct neuronal populations are not
strictly localized in neuroanatomically seperate cell groups, but are spread over
many areas of the brain. Despite these alterations the essence of the model has
remained the same: the assumption that the alternation between non-REMS and
REMS is regulated by an interaction between ACh and MA (NA & 5-HT) neurons.
Figure 3 shows the schematic representation of the model.
In 1982 McCarley suggested that these neuronal mechanisms in the regulation
of the non-REMS-REMS cycle would also play a role in mood regulation. He pro-
posed the hypothesis of a common pathophysiological mechanism underlying
both REMS disturbance and depression. A depressive state is supposed to be the
expression of a relatively decreased MA activity in combination with a relatively
increased ACh activity. According to this hypothesis both the disturbance of
mood and of sleep are manifestations of a disturbed Ach-MA balance. The
increase of REMS at the beginning of sleep in depressives would be caused by
insufficient suppression of REMS by the MA system. In other words, short REMS
latency in depression could reflect an increased ratio of Ach versus MA activity.
T o date, the role of the ACh side of REMS regulation is probably better suppor-
ted than the MA side (see reviews by Gillin and Shiromani, 1990; Dube, 1993).
As initially proposed by j anowsky et al. (1972) in the cholinergic supersensiti-
vity hypothesis of m o o d disorders, depression is associated with a relative
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Figure 3. Schematic representation of the ACh-MA balance model. The assumed neurochemical identi-
ty of the REMS-inhibitory neuronal populations is listed in the left box, and that of the REMS-promo-
ting populations is indicated in the right box. During waking the cell populations with NA and 5-HT
activity inhibit those with ACh activity. Over the course of the sleep cycle, die inhibitory MA (norepi-
nephrine & serotonin) influences diminish becatise of negative (inhibitory) feedback: when pontine
reticular formation neurons are released from inhibition, they become active and, using ACh, generate
the events of REMS (after McCarley, 1982).
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increase in ACh sensitivity, and mania with decreased sensitivity. As applied to
sleep in depression, the hypothesis postulates that shortened REMS latency is
another manifestation of ACh supersensitivity. In support of heightened ACh
sensitivity in depression, the administration of ACh agonists such as arecoline
leads to a more rapid appearance of REMS in depressed patients than in controls
(Sitaram et al, 1980; 1982). However, Berger et al. (1983) did not find a diffe-
rential effect of the ACh agonist physostigmine in depressed patients, in part
because of the awakenings induced by physostigmine.
Recently, it has been shown that the cholinomirnetic drug RS 86 (a spiropipe-
ridyl derivate), given orally before bedtime, results in sleep with shortened
REMS latency in depressives (Berger et al., 1985). The same group was able to
show that RS 86 provoked REMS onset periods (REMS latency < 25 min) in 14 of
16 depressed patients (Berger et al., 1985; 1989). Subjects with personality dis-
orders or an eating disorder, even with a concomittant major depression,
showed REMS induction by RS 86 comparable to that in healthy controls and
were clearly distinguishable from depressed subjects (Lauer et al., 1988; Berger
et al.,1989). In contrast to the original study with arecoline (Sitaram et al.,
1982), Berger et al. (1989) did not find a positive effect in depressive patients in
remission. In another study Berger et al. (1991) could not demonstrate a signi-
ficant difference in RS 86-induced sleep onset REMS periods between patients
with schizophrenic disorders and patients with depression. The pronounced
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shortening of REMS latency in the schizophrenic patients mainly occurred in the
subjects with a chronic course of the disorder or a secondary depression.
Although there are differences between these studies with respect to applied
methods, they do support the hypothesis that patients with depression show
enhanced REMS response to Ach agonists. Because the underlying mechanism of
the amplified response to cholinergic stimuli in depressives is unknown, the
interpretation of the role of Ach mechanisms, in terms of REMS dysregulation
remains largely speculative at this time (Gillin and Shiromani, 1990).
Despite the seemingly simple regulatory scheme of the Ach-MA imbalance
model, still no clear picture exists of the neurophysiological mechanisms invol-
ved (Steriade and McCarley, 1990). Although many studies have been publis-
hed on the effects of various drugs and endogenous substances on the sleep of
animals and man (see reviews by Jouvet, 1977; Mendelson, 1987; Borbely and
Tobler, 1989; Gaillard, 1990), the interpretation in terms of neurophysiological
processes is very difficult. To date, no single neurotransmitter, neuromodulator
or neurohormone has been identified as being responsible for the generation
and maintenance of REMS or non-REMS. Instead, multiple factors and systems
appear to be involved in the regulation of these sleep states. Therefore, the dis-
turbances in sleep in depressed patients cannot, according to present knowled-
ge, be derived simply from, for example, a global abnormality in brain MA or
ACh function (Fernstrom and Pastel, 1989; Mendelson, 1991).
Although it is unlikely that there is only one neurotransmitter system involved,
several lines of evidence suggest that the 5-HT system in particular may play an
important role in sleep regulation as well as in the pathogenesis and recovery of
depression.
The involvement of the 5-HT system in sleep has been suggested for more
than 20 years (Jouvet, 1969). There is renewed evidence from animal studies
that the 5-HT system is involved in sleep regulation, albeit in a complex way
(Cespuglio et al., 1992). Furthermore, reduction of REMS is a feature of most
drugs which alter 5-HT-mediated transmission (Nicholson and Pascoe, 1988).
In some types of depression it has been proposed that there is 5-HT underacti-
vity and that therapeutic actions of ADs are due to reversal of this deficiency
(Asberg et al., 1984; Van Praag, 1986). The 5-HT metabolism in depressive dis-
orders is reviewed by Van Praag (1980; 1982), Meltzer and Lowy (1987) and
Brown et al. (1991). The results suggest that the metabolism of this amine is
altered in some patients with depression. Recently, results from electrophysio-
logical single-cell recording studies in animals strongly suggest that most, if not
all, types of antidepressant treatments (i.e. MAOIs, tricyclic ADs, 5-HT uptake
inhibitors, electroconvulsive shock treatment, and possibly sleep deprivation),
share an enhancement of 5-HT neurotransmission, although each of these inter-
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ventions achieve this enhancement through different mechanisms (Blier et al.,
1987). Blier et al. conclude that intensification of 5-HT-function appears to be a
common element of antidepressant treatments. They also suggest that this
modification may only be one link in a chain of several events leading to an
antidepressant response.
In summary, the results from fundamental animal research suggest that the
balance between Ach and MA systems is involved in sleep cycle control.
However, present empirical knowledge from pharmacological sleep research
has not provided an explanation of the effects of ADs on sleep in depressives in
the context of the Ach-MA balance model. Therefore, the hypothesis of a com-
mon pathophysiological mechanism underlying both REMS disturbance and
depression still lacks a sound empirical pharmacological basis. •
1.4.3. The two-process model of sleep regulation, and the S-defi-
ciency and non-REMS hypotheses
The third theoretical approach to explain the effects of ADs on depression in
sleep physiological terms is based on the two-process model of sleep regulation
(Borbely, 1982; Daan et al.,1984). The central assumption is that two separate
processes underlie the regulation of the sleep-wake cycle, a homeostatic process
S and a circadian process C (see Fig. 4).
Figure 4. The two-process model of sleep regulation (modified from Daan et al., 1984). W =
waking; S = sleep. For explanation see text.
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Process S reflects sleep need, and its level declines and rises exponentially
during sleep and during waking, respectively. The value of process S is suppo-
sed to be exclusively dependent on the history of sleep and wakefulness; in
other words, the level of S is fully determined by the duration of prior wakeful-
ness and thus is supposed to reflect sleep need or sleep debt, c.q. sleep intensity.
Process C, which varies over the 24-hour period, is supposed to be indepen-
dent of sleep and waking, but exclusively determined by the biological clock
located in the suprachiasmatic nuclei in the hypothalamus. Process C sets
thresholds to process S: it interacts with process S so as to control both the
time of sleep onset and of sleep termination. Process S is assumed to be reflec-
ted in the EEG power of non-REMS, assessed by spectral analysis. Borbely et al.
(1981) demonstrated in normal subjects that the power of the sleep EEG shows a
continuous slowly declining course across subsequent non-REM-REMS cycles.
Since most of the power is present in the low frequency bands (1-4 Hz), total
power values largely reflect the power in slow wave sleep (i.e. slow wave activi-
ty, SWA^ ) (see Fig.5).
The focus of quantitative elaboration of the two-process model has been large-
ly the dynamics of S and the shape of C. The rise rate of process S was obtained
by interpolating the EEG power values at the beginning and the end of normal
sleep periods and the beginning of sleep after sleep deprivation. In addition,
naps were scheduled in the course of the day in order to obtain intermediate
data points (Dijk et al., 1987a), The shape and phase-position of Process C
were estimated on the basis of data from sleep timing experiments (Daan et al.,
1984).
The two-process model of sleep regulation has proven to be very successful
in predicting the energy of the EEG signal, as a function of the duration of the
preceding waking period, in both humans and in various animal species (see
review by Borbely and Achermann, 1992). The longer the duration of prior
wakefulness, the higher the EEG power in non-REMS. Moreover, it is possible to
quantitatively predict within one night the non-REMS power increase after tem-
porary suppression of SWA (Dijk et al., 1987b). Clearly, non-REMS power is
subject to homeostatic control. The neurophysiological mechanisms under-
lying this homeoscasis are unknown at the moment.
Based on the two-process model of sleep regulation an S-deficiency hypothesis
of depression was formulated (Borbely and Wirz-Justice, 1982; Borbely, 1987).
This postulates that during the waking period of depressive patients process S
does not rise to the level which is attained in non-depressive subjects. Thus the
•' It should be noted that SWA is not identical with SWS which is a substate of non-REMS defined by
arbitrary criteria (Borbely, 1987). . <
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Figure 5. Sleep states and EEG power density plots of a healthy subject. Sleep states (top) are plotted
for 30-s epochs. Power density of the various frequency bands is plotted for 1-rain segments. The
non-REMS-REMS cycles are delimited by vertical lines (after Borbely et al., 1982; 1986).
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build-up of process S is supposed to be deficient, which results in a low level of
S at the beginning of sleep. It is further assumed that the level of S is of causal
importance for depression (see Fig, 6). .- : •;,•; .- > : ^ .-: ; • • .- •••.•••••.•-•••
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Figure 6. Diagram of the S-deficiency hypothesis of depression. A lower level of S corresponds
with a more depressed mood. The improvement by total sleep deprivation is related to the increase
of the level of S. The upper and lower S-threshoIds are indicated by II and L respectively (modified
from Borbely and Wirz-Justice, 1982).
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At first sight this so called S-deficiency hypothesis offers an explanation for
the sleep characteristics of depressed patients. Since the level of process S deter-
mines the duration and intensity of sleep, a low level must lead to shorter and
shallower sleep. The hypothesis also suggests an explanation of the therapeutic
effect of sleep deprivation: sleep deprivation results in an increased level of pro-
cess S and, therefore, in a decrease of depressive symptomatology. After reco-
very sleep process S becomes deficient again and depression becomes worse.
At the moment, evidence concerning the S-deficiency hypothesis of depression
and therapeutic sleep deprivation is inconsistent. In a theoretical study,
Beersma et al. (1985) used the two-process model to simulate the sleep distur-
bances in depression. They concluded that classical features, such as reduced
sleep time and impairment of sleep continuity, could best be simulated by
introducing "noise" in process C, rather than by lowering the build-up of pro-
cess S. Two empirical studies have shown that EEG power density of non-REMS
was abnormally low in depressives (Borbely et al., 1984; Kupfer et al., 1984).
However, two other studies (Mendelson et al.,1987; Van den Hoofdakker et al.,
1986) provided no evidence of differences in total EEG power production
between healthy and depressed subjects, even though conventional sleep poly-
graphic variables showed reduced sws in the depressives. Van den Hoofdakker
et al. (1986) only observed an altered distribution of EEG power over the night
in depressives. Compared to healthy subjects the depressives produced relative-
ly less EEG power in non-REMS during the first hours of sleep and relatively
more power during the later hours.
The prediction of the S-deficiency hypothesis that augmentation of process S
is responsible for the therapeutic effect of sleep deprivation was also not sup-
ported. The improvement of depression after one night 's total sleep deprivation
appeared not to correlate with the increase of power production during reco-
very sleep relative to the production in baseline (Van den Hoofdakker and
Beersma, 1986; 1992).
Recently, several studies using spectral analysis of the sleep EEG have been
reported, which are noteworthy concerning the possible role of non-REMS in
depression. Beersma et al. (1990) deprived a group of nine healthy volunteers
from REMS by arousing them when REMS occurred during the first 5 hours of
the night. During the rest of the night sleep was undisturbed. In a control con-
dition non-REMS was interrupted just as often and dur ing the same 5-hour
interval. The REMS deprivation condition resulted in a REMS rebound and, sur-
prisingly, in a reduction of the non-REMS EEG power during the undisturbed
part of the night, despite the fact that non-REMS had not been disturbed experi-
mentally. The authors concluded that these results strongly suggest that a high
pressure for REMS suppresses the intensity of non-REMS. Dijk et al. (1991) stu-
died the effect of the AD clomipramine on sleep in chipmunks (a day-animal
with a circadian sleep-wake rhythm comparable to that of humans) . They
found that under clomipramine the amount of REMS and the EEG power of non-
REMS were considerably decreased. So, just as during non-pharmacologically
induced REMS deprivation, under clomipramine too, both REMS and the intensi-
ty of non-REMS are suppressed.
These observations have led to the assumption that the antidepressant effects
of ADs might be due to the suppression of non-REMS power rather than sup-
pression of REMS (Beersma and Van den Hoofdakker, 1992). The authors argue
further that this explanation (the so-called non-REMS hypothesis) is in agree-
ment with the majority of the data on the antidepressant effects of non-phar-
macological sleep manipulations, such as total and partial sleep deprivation and
REMS deprivation. They all share the non-REMS intensity suppressing element,
either acutely or cumulatively. . . . . . . . . . . . . . .
In summary, the two-process model of sleep regulation and the related hypo-
theses based on it offer a theoretical framework for the explanation of the p ro -
cesses underlying antidepressive treatment effects. They predict that therapeu-
tic effects must be expected from suppression of non-REMS intensity.
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1.5. CONCLUDING REMARKS
The evidence that manipulations of sleep have clinical benefits in some depres-
sed patients and the remarkable influence of most ADs upon sleep suggest that
sleep changes are not merely epiphenomena of depression. Changes in sleep
physiological processes might, therefore, be intimately involved in the pathoge-
nesis, and the manipulations of these changes might be of crucial importance
for the recovery from depression. Although an increasing number of findings
provides arguments to consider the study of sleep as a source of insight into the
physiological background of mood disturbance and antidepressive interven-
tions, the empirical foundations of the prevailing models are still weak (Van
den Hoofdakker and Beersrna, 1988).
The best documented effects of most efficacious ADS on sleep polygraphic
variables in man are REMS suppression and lengthening of REMS latency, irre-
spective of their pharmacological profile. It is clear, as shown earlier, that some
ADs do not share these REMS suppressing properties. Nevertheless, the thera-
peutic effect of selective REMS deprivation by arousals and the effects of most
efficacious ADs on REMS suggest that strong initial and sustained REMS pressure
is a prerequisite for the improvement of depression. The reports on a direct
relationship between changes of REMS produced by ADs and clinical response
are scarce and contradictory. Further clinical sleep research is therefore needed
to elucidate the therapeutic importance of the effects of ADs on REMS during
treatment.
A significant therapeutic role for changes of REMS is also postulated by the
ACh-MA balance model and its related hypothesis of a common pathophysiolo-
gical mechanism underlying both REMS disturbance and depression. However,
the latter hypothesis cannot be tested clinically, because the Ach-MA balance
cannot be measured directly in man in the relevant brain structures. Indirect
evidence may be expected from clinical sleep research with ADs modifying the
ACh and MA neurotransrnitter systems specifically. As was shown earlier, ADs
which modify the 5-HT system specifically could be relevant in this respect.
The hypotheses, based on the two-process model of sleep regulation, predict
that the suppression of EEG power in non-REMS rather than the suppression of
REMS is of therapeutic importance. These hypotheses have not been tested
during treatment with ADs.
In summary, considering the empirical facts on the influence of ADs on sleep,
and the prevailing conceptual backgrounds on the link between sleep and
depression, further studies on the effects of ADs on REMS as well as on non-
REMS power in depressives are highly needed. In such studies the relationship
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between changes in sleep and in clinical state must be measured over a clinically
significant treatment period.
1.6. CLINICAL STUDIES OF THIS THESIS
Two studies were performed. One with the AD trazodone (chapters 2 and 3),
the other with the AD citalopram (chapters 4 and 5). The clinical change of sub-
jects suffering from a major depression was compared to the changes in sleep
variables obtained by visual scoring and by spectral analysis of the non-REMS
EEG during treatment. The studies have the same single blind design: a medica-
tion period of 5 weeks is preceded and followed by one-week placebo treat-
ment. The sleep recordings were analyzed in successive 30-s epochs according
to the scoring rules of Rechtschaffen and Kales (1968). Fast Fourier transfor-
mation' was performed in such a way as to enable spectral-analytical evaluation
according to Borbely et al. (1981).
The AD trazodone was chosen, because it had been reported earlier (Mouret
et al., 1988) that this AD did not suppress REMS in depressives, whereas REMS
latency, SWS and sleep efficiency were increased. The effects of t razodone on
sleep thus seemed to question the significance of REMS suppression in the phar-
macological alleviation of depression. The aim of our study (chapter 2) was to
contribute to this controversial issue by comparing the changes in sleep poly-
graphic variables and antidepressant effects of t razodone more precisely. In
chapter 3 the influence of trazodone on EEG power density of non-REMS is pre-
sented and discussed.
The AD citalopram was chosen for the second study because this compound is
one of the most selective 5-HT inhibitors currently available, and its metabolites
are also 5-HT specific. No human sleep data were yet known from studies in
depressives. In chapter 4 the effects of citalopram on sleep polygraphic varia-
bles and depression are examined, and in chapter 5 the influence of citalopram
on EEG power density of non-REMS is presented and discussed.
' Fast Fourier transformation (FFT) is a mathematical procedure by which a time series of n data-
points which are sampled at equal intervals, i.e. a digitized EEG signal, is decomposed in sine- and
cosine-functions of varying amplitude and frequency. In general the highest frequency considered
is the Nyquist frequency which corresponds to a period of two sampling intervals. The frequency
resolution used is 1/n*d, where d is the sampling interval; thus n*d is the duration of the whole
time series. The power in a frequency bin represents the contribution of this frequency bin to the
total power of the signal. Although the central prerequisite for FFT, i.e. stationarity of the signal,
is not met by the sleep EEG, this problem can be solved adequately by separately analyzing many
short epochs (for instance 4 seconds) which then are considered "quasi"-stationary. Data reduc-
tion can be achieved by calculating an average spectrum over a certain time interval, and by avera-
ging over adjacent frequencies (cited from Dijk, 1988).
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CHAPTER 2
Effects of trazodone on EEG sleep
and clinical state in major depression
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SUMMARY
The effects of the antidepressant trazodone on clinical state and on EEG sleep in
eight outpatients with a major depressive disorder were investigated in a single
blind study. A medication period of five weeks was preceded and followed by
one week placebo treatment. Five subjects showed a positive treatment respon-
se. Trazodone did not influence sleep continuity and slow wave sleep, but did
suppress REM sleep significantly. A significant increase of REM sleep latency was
also found. These results are in contrast with earlier reports on trazodone's
effects on EEG sleep but are in accordance with the general finding that antide-
pressants influence REM sleep characteristics without necessarily affecting sleep
continuity.
INTRODUCTION
The sleep of subjects with a major depressive disorder shows frequent distur-
bances: prolonged sleep latency, frequent awakenings, early sleep termination,
diminished slow wave sleep (sws), shortened rapid eye movement (REM) sleep
latency, and large variability in non-REM/REM cycle duration are the main char-
acteristics (Gillin and Borbely 1985). Antidepressant drugs (ADs) of all existing
neurochemical classes bring about changes in EEG sleep (Nicholson et al. 1989).
Because almost all ADs suppress REM sleep, and selective REM sleep deprivation
over 3 weeks alleviates depression, the assumption has been proposed that
strong, sustained REM sleep suppression is the key mechanism underlying treat-
ment response (Vogel 1983; Vogel et al. 1990). Although they constitute no,
general finding, the changes in sleep continuity, i.e. the reduction of nocturnal
wakefulness, and the increase of the duration of the various stages of non-REM
sleep produced by ADs might also be of therapeutic importance (Nicholson et
al. 1989). In addition to this, an increase of SWS might be relevant, because SWS
has been postulated to play an important role in the "rest and restoration"
which sleep is thought to subserve (Gillin et al. 1989).
Moure t et al. (1988) reported that the AD trazodone did not suppress REM
sleep in endogenous depressives, whereas REM sleep latency, sws and sleep effi-
c i e n c y w e r e i n c r e a s e d . A n increase in sws was further reported by
Montgomery et al. (1983) in elderly non-depressed subjects suffering from in-
somnia. In this study trazodone suppressed REM sleep and a REM sleep rebound
was observed dur ing wi thdrawal . Finally, Ware et al. (1990), studying the
effects of trazodone on the sleep of healthy young adults, reported apart from
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an increase in sws a slight REM sleep suppression and a slight lengthening of
REM sleep latency. Trazodone's effects seem to question the significance of REM
sleep suppression in the pharmacological alleviation of depression. In fact, sws
increase and amelioration of sleep continuity rather than REM sleep decrease
might be of therapeutical significance.
The aim of this study was to contribute to this controversial issue by compa-
ring the sleep physiological and antidepressant effects of t razodone more preci-
sely than was done in previous studies.
MATERIALS AND METHODS
Study design
Table 1 shows the main aspects of the study design and the dosage regimen.
There were three consecutive treatment periods encompassing a total of seven
weeks. In week 1 placebo was administered; in weeks 2-6 the subjects were tre-
ated with trazodone; in week 7 trazodone was substi tuted by placebo. The
administration of placebo and trazodone was single blind. Subjects were infor-
med, however, that placebo treatment could occur. An exception to the dosage
regimen was made for subjects whose depression failed to improve after 1 week
of treatment with trazodone at the 300 mg/day level (week 4). Their dosage
was increased to 400 mg/day (days 28-41: 1:00 p.m. 200 mg, 10:00 p.m. 200
Table 1. Study design; experimental days, dosage regimen and the schedule of the sleep recordings.
PLA= placebo
Days
1-6
7-9
10-13
14-16
17-20
21-41
(28-41)
42-48
Dosage
1:00 p.m.
PLA
PLA
PLA
50
50
100
(200)
PI A
regimen
10:00 p.m.
PLA
100
150
150
200
200
(200)
PLA
Trazodone
daily dose
<mg)
0
100
150'
200
250
300
(400)
0
Sleep
recordings
(days)
6-7
13-14
20-21
27-28
34-35
41-42
48-49
41
Subjects
The participants had to be outpatients and had to suffer from a major depres-
sion, single or recurrent ( D S M - I I I - R (APA 1987) codes 296.2 and 296.3), includ-
ing insomnia ( D S M - I H - R code 307.42). In addition to this, a score of 17 or high-
er on the Hamil ton Rating Scale for Depression (HRSD, 17 items; Hamilton
1967) was required. Subjects were only included when two psychiatrists agreed
with respect to diagnosis. Sleep disorders such as sleep apnea or nocturnal
myoclonus were not present. The results of physical examination, ECG, blood
chemistry and hematology were within normal limits. Subjects were free of
psycho-active medication for at least 1 week before participating in the study.
The protocol was reviewed and approved by the institutional Ethics Review
Committee and the subjects gave informed consent.
Measurements
The severity of depression of the previous week was assessed preceding each
sleep recording by means of the HRSD, by two independent psychiatrists. Both
preceding (evening) and after (morning) each sleep recording self-rated mood
was assessed using the Adjective Mood Scale (AMS, von Zerssen 1976). The AMS
consists of 28 items and yields a score ranging from 0 (not depressed) to 56
(very depressed). It is particularly well suited for frequent use at short intervals.
The Dutch version of the AMS has been shown to be psychometrically reliable
(Elsenga 1988). Subjective sleep quality (SQ) was assessed after each sleep recor-
ding with a self-rating questionnaire (Mulder-Hajonides van der Meulen 1981).
The SQ consists of 14 items and yields a score ranging from 0 (very good sleep)
to 14 (very bad sleep).
Sleep EEG was recorded between 11:00 p.m. and 7:00 a.m. in our sleep labora-
tory at the end of every week. The baseline night, recorded in the first week,
was preceded by an adaptation night. The recordings were made at a paper
speed of 10 mm/s from standard leads: two EOGs, two EEGs (C3-A2 and c4-Al)
and a submental chin EMG. The time constants for the EOG and EEG recordings
were 0.3 s; the high frequency cut-off was 35 Hz.
Measures
i/ stare
For every subject the average of the independent HRSD ratings was used as
index of the severity of depression. A HRSD reduction at the end of week 6 of at
least 50 % of the baseline score (week 1) was taken as criterion for a positive
treatment response. The averages between the AMS evening and morning scores
were used to monitor changes in self-rated mood.
S/ee/> recordings
These were visually analyzed in successive 30-s epochs according to the scoring
rules of Rechtschaffen and Kales (1968). The following EEG sleep parameters
were assessed (Coble et al. 1981): sleep continuity: total recording time (TRT):
from "lights out" until arising in minutes; sleep onset (so): the first epoch of
stages 2,3, 4 or REM, followed by at least 10 min of sleep interrupted by no
more than 2 min of stage 1 or wakefulness; sleep latency (SL): the time between
"lights out" and SO in minutes; end of sleep (ES): the last epoch of stages 2,3 or
4, or REM, preceded by at least 10 min of sleep interrupted by no more than 2
min of stage 1 or wakefulness; total time awake: the time awake between SO and
ES in minutes; sleep period: the time between s o and and ES in minutes; total
time spent asleep (TSA): the time spent in stages 1-4 and REM between SO and ES
in minutes; sleep efficiency: the ratio between TSA and TRT x 100 %.
iifjl/ s/eqS
REM period, the first REM period has to last at least 3 min, subsequent REM
periods have to last at least 5 min. Interruption by non-REM sleep, wakefulness
or movement time may not last more than 15 min; REM latency: the t ime
between so and the first RBM period in minutes.
S/eep stages
The time spent in each sleep stage in minutes; percentage of time spent in sleep
stages: the time spent in each sleep stage in minutes/TSA x 100 %.
Analyses • • • . . . . , , .,;••-•
A one-way MANOVA for repeated measures (O'Brien and Kister Kaiser 1985)
was applied over the seven experimental weeks. Because of the large interindi-
vidual variability in the timing of the effects of t razodone on sleep and behavi-
or, the five treatment weeks were pooled into one estimate. Subsequently, the
baseline, pooled trazodone treatment and withdrawal period were analyzed by
means of a 1x3 MANOVA for repeated measures. The Newman-Keuls ( N K ) post-
hoc procedure was used to detect where significant results were located.
P values of < 0.05 were accepted as significant. . ;, •.
RESULTS
Biographic and clinical characteristics at entrance are shown in Table 2.
Eight outpatients (six females, two males; mean age = 43.5 years, SD = 7.3)
participated in the study. Their mean HRSD score at entrance was 27.5 (SD =
3.2). Five subjects met the criterion of a positive treatment response and three
did not. The latter three received the higher dosage of trazodone. There was,
however, still no improvement at the end of week 6.
Table 2. Biographic and clinical characteristics of each subject, DSM-HI-R codes and HRSD scores at
entrance
SEX
F
F
F
F
p . ' - .
M
P
M
AGE
yrs
49
56
39
46
42
36
34
46
DSM-
III-R
296.3
296.2
2963
296.2
296.3
296.2
296.2
296.2
HRSD
22
25
30
27
32
26
28
30
R/
NR
R
R
R
R
R
NR.
NR
NR
F = female; M = male; R = responder; NR = nonresponder
Clinical state and subjective sleep
The mean values and standard deviations of HRSD, AMS (the average between
the scores prior to and after the sleep recording) and SQ scores during the seven
experimental weeks are shown in Table 3.
A MANOVA over seven weeks with the scores of HRSD, AMS (evening, morning
scores and their average separately) and SQ did not show significant results. A
1x3 MANOVA revealed a significant result in HRSD scores (F<,6 = 11.9; P = 0.01)
and no significant results for the different AMS scores and the SQ scores. The
N K procedure showed that the HRSD result could be attributed to a significant
improvement in depression dur ing the pooled trazodone treatment period
compared to baseline. There was no significant difference between treatment
and withdrawal period.
Table 3. Clinical measures: depressive mood (HRSD), self-rated mood (AMS: the average between the
scores assessed prior and after each sleep recording) and subjective sleep quality ( S Q ) . Mean values
and standard deviations (n=8) during the 7 experimental weeks
HRSD
AMS
SQ
PB
26.3
(3.5)
35.9
(15.1)
8.0
(4.0)
Tl
20.8
(6.5)
31.2
(14.8)
6.4
(4.1)
T2
14.5
(8.5)
32.9
(14.2)
8.9
(3.0)
T3
16.4
(9.8)
31.0
(16.8)
6.4
(3.3)
T4
15,5
(8.3)
33.5
(14.3)
6.1
(3.6)
T5
11.6
(9.4)
27.2
(16.8)
6.3
(3.1)
PW
16.5
(8.5)
26.2
(17.8)
7.3
(3.7)
PB = placebo baseline; T1-T5 = the 5 trazodone treatment weeks; PW = placebo withdrawal
Sleep continuity and REM sleep latency
The mean values and standard deviations of sleep continuity parameters and
REM sleep latency during the seven experimental weeks are shown in Table 4.
Neither 1x7 MANOVA nor 1x3 MANOVA yielded significant results for the diffe-
rent indicators of sleep continuity, i.e., sleep latency, sleep period, total time
asleep, total time awake, and sleep efficiency. Although 1x7 MANOVA did not
produce a significant result for REM sleep latency, a 1x3 MANOVA did (Fw = 6.1;
P = 0.04). The NK procedure showed that this was due to a significant lengthe-
ning of REM sleep latency during the pooled trazodone treatment period com-
pared to either baseline or withdrawal.
Sleep stages > .
The mean values and standard deviations of the sleep stages (minutes and per-
centage) during the seven experimental weeks are also shown in Table 4. A
MANOVA over seven weeks showed only a significant result for stage non-REM 2
(minutes: Fv = 26.5; P=0.04; and percentage: Fi.t = 27.6; P=0.04). NK posthoc
analysis revealed that this result could not be attributed to significant differen-
ces between specific period pairs. A 1x3 MANOVA revealed significant results for
all sleep stages, expressed either in minutes or in percentage: non-REM 1 (minu-
tes: Fy =10.7; P=0.01; percentage: F« = 13.7; P=0.01), non-REM 2 (minutes: F2*
= 30.6; P < 0.01; percentage: Fw = 94.3; P < 0.01), non-REM 3 & 4 (minutes : F ^
= 8.1; P = 0.02; percentage: F« = 6.4; P = 0.03), REM (minutes: F « = 25.9; P <
0.01; percentage: F.v, = 30.2; P < 0.01). The NK procedure showed the following:
Table 4. Sleep measures as derived from the EEG sleep recordings. Mean values and standard devia-
t ions (n=8) during the 7 experimental weeks
PB Tl T2 T3 T4 T5 PW
Sleep c o n t i n u i t y and REM sleep l a t ency
Sleep
latency
Sleep
period
Total time
asleep
Total tiine
awake
Sleep
efficiency
REM sleep
latency
Sleep stages (min)
Stage 1
Stage 2
Stages 3&4
Stage REM
59.6
(31.8)
398.8
(28.7)
362.3
(39.6)
36,5
(25,9)
76
(8)
97.0
(34.5)
28.4
(9.5)
220.3
(25.6)
36.7
(27.1)
76.9
(16,6)
50.3
(14.2)
396.9
(41.7)
372.9
(41.8)
24.0
(29.3)
79
(8)
192.9
(47.8)
35.4
(23.9)
253.6
(46.1)
34.8
(28.5)
49.1
(27.8)
37.9
(16.5)
409.6
(40.1)
383.7
(40.1)
25,9
(23.1)
82
(8)
221.1
(98.7)
31.4
(19.9)
258.6
(38.5)
50.4
(30.6)
43.3
(24.2)
Sleep stages {% from total time spent asleep)
Stage 1
Stage 2
Stages 3&4
Stage REM
7.8
(2.5)
60.8
(6.5)
10.1
(7.2)
21.2
(3.4)
9.5
(6.2)
68.0
(8.1)
9.3
(9.0)
13.2
(7.4)
8.2
(5.3)
67.4
(7.6)
13.1
(7.9)
11.3
(5.6)
38.3
(14.5)
423.6
(21.8)
401.8
(38.7)
21.8
(22.6)
85
(7)
137.6
(37.8)
31.5
(12.1)
269.1
(48.1)
38.8
(25.3)
62.4
(14.4)
7.8
(2.8)
67,0
(7,5)
9,7
(6.5)
15.5
(3.6)
45.4
(29.5)
406.5
(56.0)
389.4
(53.3)
17.1
(10.9)
82
(H)
157.9
(108.8)
35.9
(26.4)
262.1
(62.3)
43.1
(30.6)
48.3
(19.1)
9.2
(6.1)
67.3
(9.2)
11.1
(9.3)
12.4
(5.5)
35.3
(20.7)
417.7
(32.1)
396.4
(29.8)
21.3
(11.1)
85
(6)
156.9
(61.0)
39.6
(18.0)
248.1
(48.2)
45.8
(30.4)
62.9
(29,9)
10.1
(4.6)
62.6
(11.1)
11.6
(8.4)
15.9
(7.0)
42.8
(40.1)
409,2
(44.3)
385.0
(51.6)
24.2
(12.8)
83
(11)
84.3
(47.8)
56.7
(16.6)
215.7
(56.4)
25.0
(21.5)
87,6
(17.8)
14.7
(3.5)
56.0
(9.9)
6.5
(6.0)
22.8
(5.5)
PB = p l a c e b o basel ine; T1-T5 = t h e 5 t r a z o d o n e treatment weeks; PW = placebo withdrawal
the non-REM 1 result could be attributed to a significant increase in non-REM 1
sleep during the withdrawal period compared to either the baseline or the tra-
zodone treatment period. The non-REM 2 result could be attributed to a signifi-
cant decrease in non-REM 2 sleep during the withdrawal period compared to
either baseline or trazodone treatment period. The NK procedure failed to show
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where a significant overall difference in stage non-REM 3 and 4 was located. The
REM sleep result could be attributed to a significant decrease of REM sleep
during the trazodone treatment period compared to both baseline and withdra-
wal.
Comparison of RRM sleep, REM sleep latency and SWS in respon-
ders and nonresponders
The weekly changes in severity of depression (HRSD scores), REM sleep (min),
REM sleep latency and SWS (min) for each subject are shown in Fig. l .
Fig.l. The course of mood (total HRSD-score) (A), REM sleep (B), REM sleep latency (C) and SWS
(D) for each subject (weekly measurements). The values are expressed relative to the values of the
placebo baseline period. Solid lines = responders; broken lines = nonresponders . PB = placebo base-
line week; T1-T5 = the 5 trazodone treatment weeks; PW = placebo withdrawal week
DEPRESSIVE MOOD
PERCENTAGE
PB Tt T2 T3 T4 TS PW PB T1 T2 TS "R TB P»¥
REM SLEEP LATENCY SLOW HIVE SLEEP
PB T1 T2 T4 T6 PW PB T l T2 T8 T4 T8 PW
U p o n inspection, the major differences between responders (n=5) and nonre-
sponders (n=3) are the following. Compared to trazodone treatment week 5, an
increase of REM sleep duration is observed in all responders and in one nonre-
sponder during withdrawal of trazodone (Fig. IB). Furthermore, compared to
trazodone treatment week 5, all responders show a decrease of REM sleep laten-
cy during withdrawal (Fig. 1C). With respect to SWS responders and nonre-
sponders do not show obvious differences (Fig. ID).
DISCUSSION
Trazodone proved to be an effective AD, at least as reflected in the HRSD ratings
made by two independent psychiatrists. Trazodone, however, did not improve
significantly self-rated mood nor did it improve subjective sleep quality. The
difference between the results for HRSD and AMS might be caused by the diffe-
rence in period over which mood was evaluated. HRSD ratings reflect the global
clinical state of the patient during the previous week, AMS scores concern the
state at the moment of scoring.
The statistical analyses revealed that trazodone did not change sleep continui-
ty, but suppressed REM sleep and increased REM sleep latency significantly.
These parameters returned to baseline values after one week placebo-withdra-
wal. In spite of the absence of change of non-REM stages 1 and 2 during trazo-
done treatment compared to baseline, these stages appeared to change signifi-
cantly during one week placebo-withdrawal of trazodone, i.e., stage 1 increased
and stage 2 decreased. These findings suggest that withdrawal of trazodone
might have caused a lighter sleep. MANOVA further provided a significant diffe-
rence in the distribution of SWS over the conditions. By post-hoc analysis these
differences could not be elucidated. There is some indication that trazodone
increased SWS time and that withdrawal caused a rebound decrease. The data,
however^ are merely suggestive. Furthermore, the present study did not show a
clear-cut relationship either between clinical response and SWS or between clini-
cal response and REM sleep parameters.
O u r results are only partly in agreement with those of Mouret et al. (1988).
These authors also found an increased REM sleep latency in their depressed sub-
jects, but the increase in sleep duration and in SWS duration, and the absence of
REM sleep suppression in their study are at variance with our findings. The stu-
dies, however, are not completely comparable. In the study of Mouret et al.
(1988) only the initial effects of trazodone on EEG sleep and those after 4 weeks
of t r azodone adminis t ra t ion were assessed, whereas in our study a weekly
monitoring provided the basis for the results. An inspection of our data in the
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first and fourth treatment week with those of Mouret also suggest no agree-
ment between the two studies. The disagreement may be due to two factors:
differences in dosage regimen and in baseline sleep. In Moure t et al.'s s tudy
higher and variable dosages were employed (mean daily dosage of 422-570 mg),
while the baseline sleep characteristics indicate more severe sleep disturbances;
particularly the much lower amount of sws, both in minutes and percentage,
may be relevant. Comparison of our results with those of Montgomery et al.
(1983) and Ware et al. (1990) has also limited value, mainly because these stu-
dies concerned nondepressed subjects and lower daily dosages of t razodone
were used (respectively 150 and 200 mg).
We therefore conclude that trazodone is an AD that induces a distinct decrease
in REM sleep, whereas its effects on SWS are less clear. These results suggest that
the effects of trazodone on EEG sleep are in accordance with the general finding
that ADs influence REM sleep without necessarily affecting sleep cont inui ty
(Vogeletal. 1990).
The hypothesis of Vogel (1983) that strong, sustained REM sleep suppression
is responsible for improvement of depression is not confirmed by the results of
the present study. An alternative explanation, however, is feasible. According
to a recent model on the link between sleep and depression non-REM sleep rath-
er than REM sleep parameters are of crucial importance for the depressive state
(Borbely 1987). According to this model the pressure for non-REM sleep as
expressed in the power density in the sleep EEG is deficient in depression and
therapeutic effects must be expected from an increase of this pressure. Borbely
et al. (1981) have demonstrated in normal subjects that the power density of the
sleep EEG revealed within individual non-REM sleep stages marked, progressive
alterations that could not be recognized on the basis of visual scoring of the
sleep EEG. Recently, it was shown that REM sleep suppression produces an
increased pressure for non-REM sleep in healthy volunteers (Beersma et al.
1990). Furthermore, it should be mentioned that in chipmunks the administra-
tion of the AD clomipramine resulted not only in REM sleep suppression, but
also in a dramatic decrease in non-REM sleep intensity and therefore probably
an increase in the pressure for non-REM sleep (Dijk et al. 1991). The results of
both studies indicate that the antidepressant effect of REM sleep reduction may
be due to the reduction of non-REM sleep intensity it entails. In a next analysis
of our data this possibility will be examined by analyzing the effects of trazo-
done on non-REM sleep intensity as expressed by the EEG power density.
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SUMMARY
Recently it was hypothesized that suppression of EEG slow wave activity (SWA)
would be essential for the antidepressant action of various antidepressant treat-
ments. According to this hypothesis one would expect a relationship between
SWA suppression and improvement. This expectation is examined in this paper.
Eight outpatients with a major depression were treated with trazodone in a
single-blind design. Five weeks of trazodone treatment were preceded and fol-
lowed by one week of placebo treatment. Sleep was recorded at the end of
every week. The effects on SWA were evaluated on the basis of power spectrum
analysis. During trazodone treatment the 13 and 14 Hz bins showed a signifi-
cant reduction in EEG power . Although four out of five clinically improved
subjects (> 50 % reduc t ion of their Hamilton Depression Rating Score)
demonstrated a lowering of EEG power during and after treatment, there was
n o overall significant relat ionship between power suppression and clinical
improvement.
INTRODUCTION
The most consistently reported effects of most antidepressant drugs (ADS) on
sleep in both healthy and depressed subjects are reduction of the amount of
Rapid Eye Movement Sleep (REMS), and lengthening of REMS latency, while a
REMS rebound is observed during withdrawal (Vogel et al, 1990). The effects of
ADs on REMS and the therapeutic effects of repeated REMS deprivations over 3
weeks have led to the hypothesis that sustained REMS suppression is a signifi-
cant factor in the mechanism underlying recovery from depression (Vogel et
al., 1975). Studies in depressivcs with various ADs, however, could not demon-
strate a direct relationship between the amelioration of depression and REMS
suppression (Riemann and Berger, 1990; Van Bemmel et al., 1992).
The reports on the effects of ADs on non-REMS are inconsistent. Tricydic ADs
have been reported to increase, decrease or not affect non-REMS (Mendelson,
1989; Nicholson et al., 1989). It is not clear whether the effects on non-REMS are
related to the effects on mood. This may be due to the fact that it is not suffi-
cient to quantify non-REMS in terms of its duration only. Borbely et al. (1981)
have demonstrated in healthy subjects that the power density of the sleep EEG
(which is proport ional to the square of the EEG amplitude) within individual
non-REMS stages revealed marked alterations that could not be recognized on
the basis of visual scoring of the sleep EEG. This type of analysis might perhaps
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reveal relationships between non-REMS and mood which cannot be detected on
the basis of classical non-REMS analysis.
According to a model on the link between sleep and depression the pressure
for non-REMS as expressed in the power density of the sleep EEG is deficient in
depression and therapeutic effects could be expected from an increase of this
pressure, e.g. by sleep deprivation (Borbely and Wirz-Justice, 1982; Borbely,
1987). Recently, it was shown in healthy subjects that REMS deprivation by
arousals resulted in a simultaneous reduction of slow-wave activity (SWA) in
non-REMS (Beersma et al, 1990). In chipmunks it was demonstrated that the
administration of the AD clomipramine resulted not only in REMS suppression,
but also in a decrease in non-REMS power of frequencies between 1.5 and 13.5
Hz (Dijk et al., 1991). It has been hypothesized that the antidepressant effect of
REMS reduction may be due to the reduc t ion of non-REMS SWA it entails
(Beersma and Van den Hoofdakker, 1992). Summarizing, according to both
hypotheses ADs might be effective because of the non-REMS power suppression
during treatment.
In an earlier report on the patients in the present study (Van Bemrnel et al.,
1992) it was shown that during trazodone treatment REMS decreased and REMS
latency increased, whereas visually scored slow wave sleep (sws) did not change
significantly. The REMS variables returned to baseline values after one week
placebo-withdrawal. Furthermore, no clear-cut relationships between clinical
change and REMS variables, and between clinical change and visually scored sws
could be found. The present report concerns an analysis of the relationship
between changes in EEG power density and clinical improvement.
MATERIALS AND METHODS
Study design
Table 1 shows the main aspects of the study design and the dosage regimen.
There were three consecutive treatment periods encompassing a total of seven
weeks. In week 1 a placebo was administered; in weeks 2-6 the subjects were
treated with trazodone; at the end of week 6 trazodone was abruptly disconti-
nued and substituted by a placebo. The administration of the placebo and tra-
zodone was single-blind. Subjects were informed that placebo treatment could
occur. An exception to the dosage regimen was made for subjects whose
depression failed to improve after 1 week of treatment with trazodone at the
300 mg/day level (week 4). Their dosage was increased to 400 rng/day (days 28-
41:1:00 p.m. 200 mg, 10:00 p.m. 200 mg).
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Table 1. Study design: experimental days, dosage regimen and the schedule of the sleep recordings.
I'LA= placebo
Days
1-6
7-9
10-13
14-16
17-20
21-41
(28-41)
42-48
Dosage regimen
1:00 p.m.
PLA
PLA
PLA
50
50
100
(200)
PLA
10:00 p.m.
PLA
100
150
150
200
200
(200)
PLA
Trazodone
daily dose
(mg)
0
100
150
200
250
300
(400)
0
Sleep
recordings
(days)
6-7
13-14
20-21
27-28
34-35
41-42
48-49
Subjects
The participants were outpatients suffering from a major depression, single or
recurrent [DSM-III-R (APA, 1987) codes 296.2 and 296.3], including insomnia
(DSM-II I -R code 307.42). In addition to this, a score of 17 or higher on the
Hamilton Rating Scale for Depression (HRSD, 17 items; Hamilton, 1967) was
required. Subjects were only included if two psychiatrists agreed with respect
to diagnosis. Patients with a current history of sleep disorders such as sleep
apnea or nocturnal myoclonus were excluded on the basis of a medical inter-
view. The results of physical examination, ECG, blood chemistry and hematolo-
gy were within normal limits. Subjects were free from psychoactive medication
for at least 1 week before Week 1 with placebo. During the study alcohol con-
sumption, consumption of beverages containing caffeine (from lunch time), co-
medication, and napping were not allowed. The compliance to the instruction
not to nap was not controlled for by objective measurements. The protocol was
reviewed and approved by the institutional Ethics Review Committee and the
subjects gave informed consent.
Measurements
Prior to each sleep recording the severity of depression of the previous week
was assessed by means of the HRSD, rated by two psychiatrists.
Sleep EEG of each subject was recorded between 11:00 p.m. and 7:00 a.m. at
the end of each experimental week in our sleep laboratory. The baseline night,
recorded in the first week, was preceded by an adaptation night. The recor-
dings were obtained at a paper speed of 10 mm/s from standard leads: two
EOGs, two EEGs (C3-A2 and C4-A1) and a subrnental chin EMG. The time con-
stants for the EOG and EEG recordings were 0.3 s; the high-frequency cut-off
was 35 Hz. All signals were stored on magnetic tape for off-line analyses.
Measures
For every subject the average of the two HRSD ratings was used as an index of
the severity of depression. For each assessment the rank correlations between
the two HRSD ratings obtained in all patients were calculated. The resulting
seven correlation values showed a range between 0.91 and 0.97. This indicates a
close overall correspondence ( > 80 %) between the two HRSD raters wi th
respect to the assessment of the severity of depression. An HRSD reduction at
the end of the trazodone treatment (Week 6) of 50 % of the baseline score
(Week 1) was taken as the criterion for a clinically significant improvement.
5/eep recor&gs
These were visually analyzed in successive 30-s epochs according to the scoring
rules of Rechtschaffen and Kales (1968). Sleep onset (so) was defined as fol-
lows: the first epoch, after "lights out", of stages 2,3. 4 or REM, followed by at
least 10 min of sleep, interrupted by no more than 2 min of stage 1 or wakeful-
ness.
One PEG signal [i.e. in each subject obtained from the same lead in all condi-
tions (C3-A2 or C4-A1)] was low-pass filtered for spectral analysis at 25 Hz (24
dB/oct) and subsequently digitized at 64 samples/s. Digitized data were proces-
sed by a fast Fourier transform routine. Power spectra were calculated over 4-s
intervals from 0.75-15 Hz in 0.25 Hz bins, by applying a rectangular window.
The 0.25 bins were condensed into 1 H Z wide frequency bins. Bins will be
referred to by mentioning their upper limit, so power density in the 1 Hz bin is
the sum of the power density of 0.75 and 1 Hz; power density in the 2 HZ bin is
the sum of the power density of 1.25,1.50, 1.75 and 2 Hz etc. To obtain a reso-
lution of 30-s, power values of 7.5 adjacent 4-s epochs were summed for each
frequency bin thus calculated. Visual scores of the same 30-s epochs were syn-
chronized with the series of power spectral epochs. Figure 1 shows an example
of the time course of EEG power density and visually assessed sleep stages de-
rived from one sleep recording.
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Figure 1. Time course of EEG power density (UVVHZ), integrated from 0.75 to 15 Hz, and sleep sta-
ging from one sleep recording during placebo-withdrawal (from subject B: male, 46 yrs). (N)REM =
(non) rapid eye movement sleep; MT = movement time
22.30 23.30 0.30 1.30 2.30 3.30 4.30 5.30 6.30 7.30
The influence of trazodone on non-REMS power was analysed on the basis of
the longest common amount of non-REMS stages 2,3 & 4, accumulated from
sleep onset onwards (see Discussion). 30-s epochs of non-REMS stages 2, 3 & 4
containing EEG-artefacts [mean: 5.9 % (SD = 2.8) of all non-REMS 2, 3 & 4
epochs] were omitted from further spectral analysis, on the basis of visual
inspection of the original tracings.
Since the absolute values of the power densities of the higher frequencies are
several orders of magnitude lower than those of the lower frequencies and since
the interindividual variation is considerable, absolute values are not very suita-
ble for a visualization of changes in power spectra (Dijk et al.,1989). Therefore,
in the figures power values of each subject were expressed relative to power
values in baseline, which latter values are taken as 100 %.
Analyses
Because of the large interindividual variability in the timing of the effects of
trazodone on sleep and clinical state, for each subject the absolute EEG power
values of the different frequency bins over the five trazodone treatment weeks
were averaged into an estimate for one night. A one-way MANOVA for repeated
measures (O'Brien and Kister Kaiser, 1985) was applied over the baseline
period, the averaged trazodone treatment period and the withdrawal period.
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The Newman-Keuls (NK) post-hoc procedure was used to detect where signifi-
cant results were located. P values < 0.05 were accepted as significant.
RESULTS
Depression
Table 2 shows the clinical characteristics of the eight patients who participated
in the study.
Table 2. Age, sex (F = female; M = male), baseline HRSD scores, and changes in HRSD scores at the
end of the trazodone treatment period expressed relative to placebo-baseline values of each sub-
ject. The rank order of the subjects is based on the clinical response. Subjects A,B and C received the
higher dosage of trazodone; there was, however, still no clinically significant improvement at the
end of the trazodone treatment period
Subject
A
B
C
D
E
F
G
H
Age
yrs
36
46
34
49
42
56
46
39
Sex
M
M
F
F
F
F
F
F
HRSD
score
29
24
31
22
25
22
27
30
HKSD
change (%)
0
34
39
63
64
77
89
90
Power spectra in non-REMS , •: . •:
The longest common amount of non-REMS stages 2,3 & 4 was 168.5 minutes.
Figure 2 shows the means of the power spectra of the patient group during the
5 trazodone treatment weeks and the withdrawal period, relative to the power
spectra of baseline (= 100 %).
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Figure 2. Power spectra of 168,5 min non-REMS during the 5 trazodone treatment weeks (T1-T5)
and the withdrawal period (PW), relative to power spectra of baseline (PB = 100 %). Means of the
patient group (n=8). Power densities are plotted at the upper bounderies of the frequency bins. The
frequency ranges in which the power values varied significantly (P < 0.05; MANOVA) over the three
experimental periods (PB, T1-T5, and Pw) are indicated by black bars above the abscissa
140
120
100-
NREM POWER {%)
8 9 10 11 12 13 14 15
FREQUENCY (Hz)
The repeated measures MANOVA yielded significant results for the 1 Hz band
and the 11 through 14 Hz bands. According to the post-hoc analysis, the 5-
week trazodone treatment reduced the power density of the non-REMS EEG in
the 13 and 14 Hz bins. These values returned to baseline values one week after
placebo-withdrawal. No significant change of EEG power was found in the
lower frequency range during trazodone treatment, but a significant decrease of
the values of the 1 Hz bin one week after withdrawal compared to the 5-week
trazodone treatment was noted. The post-hoc procedure further showed that
the 11 Hz result could not be attributed to significant differences between
period pairs; the 12 Hz result could be attributed to a significant increase in EEG
power during withdrawal compared to the 5-week trazodone treatment.
60
Depression and EEG power spectra in non-REMS
Figure 3 shows the power spectra of each subject separately during the trazo-
done treatment weeks and the withdrawal period, relative to the power spectra
of baseline (=100%).
Visual inspection of the power spectra of each subject suggests that there are
major differences between clinically improved (> 50 % HRSD reduction at the
end of the trazodone treatment) and non-improved subjects. Compared to
baseline, the mean EEG energy in the delta-theta frequency range decreased
during trazodone treatment and after withdrawal in four improved subjects (D,
E, F and G). The deviant spectral response pattern of subject H (improved)
could not be related to peculiarities in clinical characteristics or visually asses-
sed sleep variables.
Figure 3. Power spectra of 168.5 niin non-REMS of each subject separately (A to H; codes correspon-
ding with those of Table 2) during the five trazodone treatment weeks and the withdrawal period,
relative to power spectra of baseline (=100 %) . Power densities are plotted at the upper bounderies
of the frequency bins. For symbols see Fig. 2.
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DISCUSSION
Before dealing with the main findings of this study we will discuss our choice
for the longest common amount of non-REMS stages 2, 3 & 4 as the basis for the
spectral analysis. In assessing the effects on non-REMS power of particular treat-
ments, there are several major pitfalls. Usually, EEG power is high during the
first non-REMS episode and low during the last one (Borbely et al., 1981).
Furthermore, EEG power waxes and wanes with the non-REMS-REMS alterna-
tion. The best simple and direct way to assess the influence of a treatment on
non-REMS power is by analyzing the effects over the longest common amount
of non-REMS, and not over a fixed EEG-interval (Kupfer et al., 1989) or over the
entire recording. The reasons for this are most easily explained in the following
examples. Let us assume that a particular treatment does not have any effects
on non-REMS power nor on total sleep time, but there are effects on intermit-
tent waking or REMS. Increased time in waking and REMS leads to reduced time
in non-REMS. As a result the contribution of the low non-REMS power values at
the end of the night will be reduced leading to the false interpretation that the
treatment interfered with non-REMS power. Alternatively, suppose that the tre-
atment induced a change in sleep duration. Since EEG power is usually low at
the end of a sleep episode, longer sleep will lead to a lower average EEG power,
even if this variable is not directly affected by the treatment. Again, one obtains
a false interpretation. Some authors have chosen to restrict the analysis to the
first non-REMS-REMS cycle in order to avoid the aforement ioned p rob lem
(Reynolds et al., 1991). However, then another problem arises. In the course of
a non-REMS episode EEG power increases towards a plateau value, followed by a
rather steep decline shortly before REMS (Achermann and Borbely, 1990). If a
treatment merely lengthens REMS latency, the EEG power plateau will last lon-
ger, and the average level of EEG power will increase, again leading to the false
impression that the treatment directly interferes with non-REMS power. In sum-
mary, the most straightforward way to study whether an AD influences non-
REMS power is by comparing the longest common non-REMS amount in baseline
and during treatment.
Our analysis resulted in the finding that during trazodone treatment the EEG
power of the 13 and 14 Hz bins during non-REMS was significantly suppressed.
No significant change was found, however, for the EEG power values of the
delta frequency range (1-4 Hz), i.e. of SWA. However, improved and nonimpro-
ved patients showed some differences in SWA changes. A decrease of SWA was
observed in four out of five clinically improved subjects and not in the unim-
proved subjects. Although these findings may suggest some suppor t of the
hypothesis that suppression of non-REMS power is involved in the reduction of
depressive symptomatology (Beersma and Van den Hoofdakker, 1992), the evi-
dence is very weak. Moreover, the number of subjects does not allow statistical
evaluation, and the results are based on comparisons with just one baseline
sleep recording.
O u r results are not in agreement with those of other studies. In the study of
Kupfer et al. (1989) on spectral analysis of EEG sleep in depressive patients tre-
ated with the AD clomipramine, the first 100 min of baseline sleep were compa-
red with the same interval of sleep after a 'loading dose' of clomipramine. It
was concluded that non-REMS power over the 100 min interval was significantly
increased in response to clomipramine. In our view this conclusion is question-
able, because the result is based on a fixed recording interval (100 min). The
dura t ion of REMS and wakefuiness within the 100-min intervals would be
expected to be very different under the two conditions. However, no data
regarding these critical issues are provided by the authors. As argued before
changes in power may have been due to other mechanisms than power sup-
pression. The same holds for the study of Reynolds et al. (1991) on the effects
of nortriptyline. They found an enhancement of SWA in the first non-REMS epi-
sode, which was correlated with clinical improvement. Again, changes in SWA
cannot be interpreted in terms of direct interference with SWA with any certain-
ty-
In summary, neither our previous analysis (Van Bemmel et al., 1992) showed
relationships between changes in duration of visually assessed non-REMS and
clinical change, nor the present analysis provided clear evidence of involvement
of non-REMS in the mechanisms underlying clinical change during trazodone
treatment.
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SUMMARY
Drug- induced improvement of depression may be mediated by changes in
sleep physiology. The aim of this study was to relate changes in sleep polygrap-
hic variables to clinical state during treatment with citalopram, a highly specific
serotonin uptake inhibitor. Sixteen patients took part. The study was single-
blind and uncontrolled. A 1-week wash-out period was followed by 1 week of
placebo administration, a medication period of five weeks, and a 1-week place-
bo period. For the entire group a significant decrease of rapid eye movement
sleep (REMS) and a significant lengthening of REMS latency were observed ini-
tially as well as at the end of treatment. No changes in sleep continuity were
found, but non-REMS stage 2 (percentage) was significantly increased. On the
basis of clinical change, as expressed by the scores of the Hamilton Rating Scale
for Depression, at the end of the citalopram treatment the patient group was
split in two halves: eight less and eight more improved patients. The groups did
not differ with respect to any sleep polygraphic variable.
INTRODUCTION
Drugs with antidepressant properties, of all existing chemical classes, not only
interfere wi th depressive symptomatology, but also cause changes in sleep
polygraphic variables (Nicholson et al. 1989). Furthermore, a number of non-
pharmacological interventions in sleep, such as total, partial or rapid eye move-
ment sleep (REMS) deprivation, ameliorate symptoms of depression (Leibenluft
and Wehr 1992). These observations suggest that changes in sleep might be
involved in the mechanisms underlying the recovery of depression.
Because nearly all antidepressants (ADS) reduce the amount of REMS (Vogel et
al. 1990), and because selective REMS deprivation over 3 weeks alleviates depres-
sion, it has been suggested that particularly strong initial and sustained REMS
suppress ion might be of central importance for the therapeutic process in
depression (Vogel et al. 1975, 1980). Kupfer et al. (1981) showed that clinical
response to amitriptyline measured after 5 weeks of treatment in 82 depressed
patients could be predicted on the basis of the amount of REMS suppression
during the first 2 nights of treatment. Gillin et al. (1978) obtained similar results
in six patients. However , clinical response after 19 days of treatment in 14
patients with the AD clomipramine [which is known for its strong REMS inhibi-
ting effect (Oswald 1973)] did not correlate with the amount of initial REMS
reduction (Riemann and Berger 1990). Furthermore, the degree of REMS sup-
pression measured weekly during a 5-week treatment with the AD trazodone in
eight patients did not show a clear-cut relationship with the course of clinical
change (Van Bemmel et al. 1992).
The reports on the effects of ADs on non-REMS do not reveal a consistent pat-
tern (Mendelson 1989). The question whether the effects on non-REMS are rela-
ted to the effects on mood is hardly studied. In the only longitudinal study on
this subject no clear-cut relation was found (Van Bemmel et al. 1992). In view
of the acute antidepressant effects of total and partial sleep deprivation (in the
later part of the night) the AD induced changes of non-REMS deserve more
attention. It has been hypothesized that an increase in non-REMS pressure might
be an important component in the mechanism underlying recovery of depres-
sion (Borbely and Wirz-Justice 1982; Beersma and Van den Hoofdakker 1992).
Summarizing, changes in both REMS and non-REMS have been proposed to
play a crucial role in the recovery of depression. However, studies on the rela-
tionships between clinical state and the magnitude of changes in sleep poly-
graphic variables during treatment with ADs are scarce. In the present study we
address this issue by analyzing the quantitative relationships between mood
changes and sleep measures during treatment with the AD citalopram. The drug
was chosen because of its high selectivity with respect to serotonin (5-HT) upta-
ke inhibition. Citalopram appears to have little effect on noradrenergic or
dopaminergic systems, and it is practically devoid of anticholinergic and anti-
histaminergic properties (Hyttel 1982). Compared to reference ADs, in particu-
lar tricyclics, the efficacy of citalopram after 6 weeks of treatment is similar
(Bech and Cialdella 1992). Citalopram has been shown to suppress REMS in cats
and to promote slow wave sleep (Hilakivi et al. 1987). No sleep data have been
published for humans.
MATERIALS AND METHODS
Study design ' : ••••• •••'•
After a 1-week wash-out period there were three consecutive treatment periods
encompassing a total of 7 weeks. In week 1 a placebo was administered; in
weeks 2-6 the subjects were treated with citalopram (week 2: 20 mg/day; weeks
3-6:40 mg/daily at 6:00 p.m.); in week 7 citalopram was substituted by a place-
bo. The administration of the placebo and citalopram was single-blind. Subjects
were informed, however, that placebo treatment could occur.
Subjects
The participants were outpatients suffering from major depression, single or
recurrent [DSM-III-R (APA 1987) codes 296.2 and 296.3], including insomnia
(DSM-III-R code 307.42). Subjects were only included if two psychiatrists
agreed on the diagnosis. A score of 20 or higher on the Hamilton Rating Scale
for Depression (HRSD, 17 items; Hamilton 1967) was required for inclusion.
Patients with sleep disorders such as sleep apnea or nocturnal myoclonus were
excluded on the basis of a medical interview. The results of physical examina-
tion, blood chemistry and hematology were within the normal range. Subjects
were free of psychoactive medication for at least 1 week before placebo-week 1
and their eligibility was decided after this wash-out period. At the end of week
1 (placebo-baseline) only subjects whose HRSD score was 20 or higher and those
with a decrease of no more than 30 % compared to the initial HRSD score after
wash-out were included. During the study alcohol consumption, consumption
of beverages containing caffeine (from lunch time), and napping were not allo-
wed. The compliance to the instruction not to nap was not controlled for by
objective measurements. No comedication was allowed. An exception was
made in cases in which subjects complained of nausea due to citalopram; these
patients received Motilium as anti-emetic medication (3 x 10 mg/day). The pro-
tocol was reviewed and approved by the institutional Ethics Review
Committee and the subjects gave informed consent. • , .
Measurements
The severity of depression of the previous week was assessed at the end of each
week by means of the HRSD, rated by two psychiatrists.
p
Subjective sleep quality was assessed after each sleep recording with a self-
rating questionnaire (Mulder-Hajonides van der Meulen 1981). The question-
naire consists of 14 items and yields a score ranging from 0 (very good sleep) to
14 (very bad sleep). During 4 separate days self-assessments were made: during
the last day of week 1 (baseline), the second day of citalopram treatment (acute
treatment), and during the last days of both week 6 (end of citalopram treat-
ment) and week 7 (after 1 week withdrawal). During these four experimental
periods self-rated depressed mood was assessed three times each day (9.00 a.m.,
5.00 p.m. and 10.00 p.m.) using the Adjective Mood Scale (AMS, von Zerssen
1976). The AMS consists of 28 items and yields a score ranging from 0 (not
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depressed) to 56 (very depressed). The D u t c h version of the AMS has been
shown to be psychometrically reliable (Elsenga 1988).
Plasma levels of citalopram (c) and desmethylcitalopram (DC) were measured at
8:00 a.m., on the last day of week 1 (baseline control), week 6 (end of treat-
ment) and week 7 (withdrawal). C and DC were analyzed according to the
method reported by Oyehaug and Ostensen (1984) with some minor modifica-
tions [mobile phase: 45% (v/v) acetonitrile in 0.5 mMol phosphate buffer pH
3.0,5.7 g/1; ammoniumperchlorate, 25% phosphoric acid to pH 2.9]. The limits
of identification and quantification were 3 and 12 nM/1 respectively for C and
DC. The intra-assay coefficient of variation (cv) was 1.3% for C and 3.3% for
DC (at 56 nM/1 for C and 58 nM/1 for DC). . • . . , • .
These were made of each subject during 7 nights between 11:00 p.m. and 7:00
a.m. in our sleep laboratory. The sleep recordings were scheduled in such a way
as to enable evaluation of the baseline characteristics of sleep (2 consecutive
nights at the end of week 1), the acute effects of citalopram on sleep (the night
after the first citalopram treatment day), the effects at the end of the citalopram
treatment period (2 consecutive nights at the end of week 6), and the effects of
1 week placebo-withdrawal (2 consecutive nights at the end of week 7). The
first baseline night was preceded by an adaptation night. The recordings were
made at a paper speed of 10 mm/s from standard leads: two EGGs, two EEGs
(C3-A2 and c4-Al) and a submental EMG. The time constants for the EOG and
EEG recordings were 0.3 s; the high frequency cut-off was 35 Hz.
Measures = . ::
Depression
For each subject the average of the two HRSD ratings during each experimental
week was used as an index of the severity of depression. For each assessment
the rank correlations between the two HRSD ratings obtained in all patients
were calculated. The resulting seven correlation values showed a range between
0.90 and 0.96. This indicates a close overall correspondence (> 80 % ) between
the two HRSD raters with respect to the assessment of the severity of depres-
sion. The average HRSD score at the end of week 6, relative to that of placebo-
baseline (week 1), was taken as a measure for the clinical change at the end of
the 5-week citalopram treatment. ,..•:..-. t ;;,.
T o moni to r changes in subjective sleep quality over the four experimental
periods the following data were used: the average of the two sleep quality sco-
res during baseline, the score of the second citalopram treatment day, the aver-
age of the two scores obtained at the end of citalopram treatment, and the aver-
age of those obtained 1 week after withdrawal. The averages of the three daily
AMS scores obtained during the four experimental periods were used to monitor
changes in self-rated depressed mood.
S/ee/> record/ings
These were visually analyzed in successive 30-s epochs according to the scoring
rules of Rechtschaffen and Kales (1968). The following additional variables
were assessed: sleep onset: the first epoch, after "lights out", of stages 2,3, 4 or
REMS, followed by at least 10 min of sleep interrupted by no more than 2 min of
stage 1 or wakefulness; end of sleep: the last epoch of stages 2, 3, 4 or REMS,
preceded by at least 10 min of sleep interrupted by no more than 2 min of stage
1 or wakefulness; REMS latency: the time between sleep onset and the first REMS
period in minutes. The first REMS period had to last at least 3 min; interruption
by non-REMS, wakefulness or movement time had to last less than 15 min.
T o monitor changes in sleep variables over the four experimental periods the
following variables were used: the averages of the sleep data at the end of week
1, the data of the night after the first citalopram treatment day, the averages of
the data at the end of week 6 and those of the data at the end of week 7.
Analyses
MANOVA for repeated measures (O'Brien and Kister Kaiser 1985) was applied
over the four experimental periods. The Newman-Keuls (NK) post-hoc proce-
dure was used to detect where significant results were located. With respect to
mood change a rank order of the patients was made on the basis of the diffe-
rence between the HRSD scores at the end of the citalopram treatment period
and those in baseline. Subsequently, the entire patient group was divided into
two: a group with relatively small changes in HRSD scores, the less improved
group, and a second group with relatively large changes in HRSD scores, the
'more improved group. Comparisons between the two groups were made by
means of MANOVA for repeated measures. Because of the skewed distribution of
the results of the self-assessments (i.e. sleep quality and AMS) log-transformed
values were used for statistical tests. P values < 0.05 were accepted as signifi-
cant. .
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RESULTS
Sixteen outpatients (seven females, nine males; mean age= 41.9 years, Sl>= 10.6)
participated in the study. Their mean HRSD score at entrance was 26.4 (SD= 2.9).
The mean clinical change of all patients was 48.5 %. The group was split in two
halves on the basis of clinical improvement. The resulting groups will be called
the "less improved" (three females, five males; mean age= 47.0 years, SD = 8.7)
with an average HRSD reduction of 28.3 % (range: 0 to 54 % ) , and the "more
improved" group (four females, four males; mean age= 36.8, SD= 10.3) with an
average HRSD reduction of 68.8 % (range: 56 to 87 % ) . The two groups did not
differ significantly with respect to age and sex. T w o patients (one in each
group) used Motilium during the second citalopram week.
Depression '. , ^
The mean values and standard deviations of HRSD scores of all patients, and
those of the less and more improved patients are shown in Table 1.
Table 1. Seventy of depression (HRSD). Mean values and standard deviations dur ing the 7 experi-
mental weeks of the entire patient group (All), the less improved ( u ) , and the more improved (Ml)
patients
WEEKS All (n=16) U (n=8) Ml ( n = 8 )
PB 26.3 (3.7) 27.9 (3.1) 24.7 (3.8)
CIT-1 21.8 (6.5) 25.9 (4.2) 16.7 (5.1)
CIT-2
CIT-3
C1T-4
CIT-5
PW
19.5
18.4
16.9
13.8
14.1
(6.4)
(7.3)
(7.8)
(6.9)
(6.8)
24.3
22.1
21.4
18.9
19.2
(4.1)
(5.1)
(5.0)
(6.1)
(5.2)
14.6
14.7
12.4
8.6
8.9
(4.6)
(7-5)
(5.2)
(2.3)
(3.4)
PB = placebo baseline; CIT-1 to CIT-5 = the 5 citalopram treatment weeks; PW = placebo withdrawal
During placebo-baseline the less and more improved patients did not differ sig-
nificantly with respect to HRSD scores (FI.H = 3.5; P= 0.09). Over the 7 experi-
mental weeks of the protocol the HRSD of the entire patient group showed a
significant variation over time (F«4 = 21.5; P < 0.01). This result could be attri-
buted to a significant change in depressive mood during the period between
weeks 2 and 6 (citalopram treatment and withdrawal) compared to baseline as
well as to the first citalopram treatment week.
Subjective sleep quality and self-rated depressed mood
The mean values and standard deviations of sleep quality and AMS scores of the
entire patient group, and those of the less and more improved groups are
shown in Table 2.
Table 2. Self-assessments: subjective sleep quality (SQ) and, self-rated depressed mood (AMS). Mean
values and standard! deviations during the 4 experimental periods of all patients (All) (n=16), the
less improved (Ll) (n=8), and the more improved (Ml) (n=8) patients
SQ
AMS
AH
u.
Ml
All
u
MI
PB
8.4
(3.0)
8.3
(3.4)
8.5
(2.8)
36.0
(14.7)
42.4
(9.0)
29.5
(17.0)
CIT-A
9.0
(2-5)
8.5
(3.0)
8.9
(2.1)
44.7
(18.0)
45.3
(9.3)
44.0
(24.7)
CIT-E
7.9
(3.4)
10.2
(1.3)
5.6
(3.3)
30.4
(14.9)
40.0
(9.8)
20.9
(13.1)
PW
8.3
(2.4)
9.3
(2.1)
7.3
(2.3)
27.6
(15.2)
37.0
(10.2)
18.1
(13.7)
I*B= placebo baseline; CIT-A= acute citalopram treatment; C1T-E= the end of citalopram treatment;
PW= placebo withdrawal
No significant variation over time was found for the sleep quality scores. A sig-
nificant variation over the four assessments was found for the AMS values of the
entire group {F,w = 7.7; P < 0.01). The post-hoc procedure failed to show,
however, where significant overall differences in self-rated depressed mood
were located. As to the less and more improved group no significant differences
in mean baseline levels of sleep quality and AMS were found. However, they
differed significantly on self-rated depressed mood measures in the course of
the experiment (Fu<= 8.2; P=0.01). A significant interaction effect between
group and time was found for sleep quality (F>,« = 5.5; P < 0.01) and for AMS
(FMJ = 2.9; P= 0.04). The sleep quality result could be attributed to a significant
improvement of subjective sleep quality in the more improved patients at the
end of citalopram treatment (Fi.n = 8.5; P = 0.01). The AMS result could be attri-
buted to a significant improvement of self-rated depressed mood in the more
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improved patients both at the end of citalopram treatment (Fun =10.8; P= 0.01)
and 1 week after withdrawal (Fi.u = 9.8; P= 0.01).
Plasma levels
The mean values and standard deviations of the plasma levels of citalopram and
desmethylcitalopram measured both at the end of citalopram treatment and
after 1-week placebo-withdrawal, for the entire patient group and for the less
and more improved groups, are shown in Table 3.
Table 3. The plasma levels (nM/l) of citalopram and desmethylcitalopram at the end of citalopram
treatment and after one week withdrawal. Means and standard deviations of the entire patient
group (All) (n=16), the less improved (LI) (n=8), and the more improved (Ml) (n=8) patients
All
u
MI
Citalopram
CIT-E
251.3
(103.2)
235.9
(91.2)
266.7
(118.0)
PW
48.1
(38.2)
34.5
(23.4)
61.6
(46.2)
Desmethyl-
citalopram
CIT-E
96.3
(43.5)
101.8
(27.4)
90.5
(56.7)
PW
35.7
(18.7)
29.0
(11.9)
42.5
(22.5)
C1T-E= the end of citalopram treatment; PW= placebo withdrawal
After 1-week withdrawal of citalopram the mean plasma level of citalopram
was decreased to 19 % and that of desmethylcitalopram to 37 % as compared
to the end of treatment. The mean of the citalopram plasma level values at the
end of the citalopram treatment was in accordance with that reported for ste-
ady-state after 40 mg citalopram daily administration [mean= 245.0 nM/ l (SD=
105.0); Overo 1982]. The less and more improved patients did not differ signifi-
cantly. : • • : : • •': -••': -V. "•' ";"•;•'- • '
Sleep continuity and REMS latency
The mean values and standard deviations of sleep continuity variables and REMS
latency of the entire patient group and of the less and more improved groups at
the four assessments arc shown in Table 4.
Table 4. Sleep continuity and REMS latency measures as derived from the sleep recordings of all
patients (All) (n=16), the less improved (Li) (n=8), and the more improved (Ml) (n=8) patients.
Mean values and standard deviations tluring the 4 experimental periods. Except sleep efficiency (=
the ratio between total time asleep and total recording time x 100 %) the values are in minutes
Sleep
latency
Sleep
period
Total time
asleep
Total time
awake
Sleep
efficiency
REMS
latency
All
U
Ml
All
LI
MI
All
u
Ml
All
LI
MI
AH
u
MI
All
LI
MI
PB
47.6
38.6
56.5
420.8
426,6
415.1
386.7
399.9
373.5
34.1
26.7
41.5
80.9
83.7
78.1
64.3
55.3
73.2
(23.0)
(22.4)
(21.1)
(25.7)
(28.3)
(23.1)
(31.1)
(25,6)
(32.0)
(22,4)
(9.8)
(29.2)
(6.7)
(5.5)
(6.9)
(48.5)
(17.9)
(67.4)
CIT-A
56.8
43.8
69.4
408.3
421.0
395.5
360.9
363.4
358.4
47.3
57.6
37.1
75.6
76.1
75.2
195.6
196.2
195.0
(40.0)
(32.5)
(50,0)
(37.8)
(28.9)
(43.0)
(54.1)
(51.2)
(60.1)
(37.5)
(38.0)
(36.4)
(11.5)
(10.6)
(13.1)
(98.9)
(98.7)
(99.1)
CIT-E
55.0
48.2
61.7
413.8
416.4
411.3
378.7
375.8
381.6
35.1
40.6
29.7
79.4
78.9
80.0
186.6
186.9
186.4
(23.0)
(21.8)
(23.5)
(22.0)
(22.4)
(22.9)
(20.1)
(19.6)
(21.4)
(16.7)
(14.9)
(17.6)
(4.2)
(3.7)
(4.9)
(56.3)
(36.9)
(73.7)
PW
61.2
53.2
69.2
403.4
406.3
400.3
364.5
361.5
367.5
38.9
45.0
32.8
76.5
75.9
77.1
66.4
61.8
71.0
(34.3)
(31.4)
(37.3)
(33.7)
(31.6)
(37.7)
(42.4)
(44.8)
(42.7)
(29.6)
(39.7)
(14.8)
(8.7)
(9.4)
(8.6)
(35.8)
(14.7)
(49.9)
I"B= placebo baseline; C I T - A = acute citalopram treatment; ClT-t= the end of citalopram treatment;
p\v= placebo withdrawal
No significant variations over time were found for the various indicators of
sleep continuity, i.e. sleep latency, sleep period, total time asleep, total time
awake, and sleep efficiency in the entire patient group. A significant result for
REMS latency was found (FJ.« = 26.0; P < 0.01). The post-hoc procedure showed
that this was due to a significant lengthening of REMS latency both during acute
citalopram treatment and at the end of citalopram treatment compared to base-
line as well as withdrawal. Neither the main effect on group (i.e. less versus
more improved) nor the interaction effect between group and time were signifi-
cant.
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Sleep stages .
The mean values and standard deviations of the sleep stages In minutes and per-
centages of total time asleep of the entire patient group and of the less and more
improved groups during the four experimental periods are shown in Table 5.
Table 5. Sleep stages. Time spent in each sleep stage in minutes , and in percentages of total time
spent asleep as derived from the sleep recordings of all patients (All) (n=16), the less improved ( u )
(n=8), and the more improved (Ml) (n=8) patients. Mean values and standard deviations dur ing the
4 experimental periods
CIT-A C1T-K
Minutes
Stage 1
Stage 2
Stages 3&4
REMS
Percentage
Stage 1
Stage 2
Stages 3&4
REMS
All
u
MI
All
u
MI
All
LI
MI
All
u
MI
All
LI
MI
All
LI
MI
All
LI
MI
All
LI
MI
36,4
36.4
36.4
234.6
248.2
221.0
18.5
6.8
30.1
97.2
108.5
85.9
9.6
8.9
10.3
60.4
62.1
58.7
5.0
1.8
8.1
25.1
27.2
22.9
(28.1)
(23.4)
(33.7)
(41.5)
(25.3)
(51.3)
(25.1)
(21.6)
(30.1)
(22.0)
(22.2)
(16.0)
(8.3)
(5.3)
(10.8)
(8.0)
(5.1)
(10.2)
(6.9)
(3.1)
(8.3)
(5.1)
(6.0)
(3.0)
40.3
42.1
38.5
252.8
263.1
242.6
20.1
10.1
30.1
47.7
48.1
47.3
12.0
11.9
12,0
69.9
72.9
66.8
5.4
2.4
8.4
12.8
12.8
12.9
(23.0)
(14.9)
(30.1)
(52.5)
(27.1)
(70.2)
(26.1)
(18.2)
(30.0)
(26.9)
(25.3)
(30.2)
(9.2)
(4.8)
(12.6)
(10.8)
(6.9)
(13,4)
(7.1)
(4.3)
(8.3)
(6.5)
(5.8)
(7.6)
49.5
49.3
49.7
253.3
260.2
246.5
14.0
7.2
20.7
62.0
59.1
64.8
13.0
13.1
12.9
66.3
69.3
64.6
3.7
1.8
5.5
16.4
15.8
17.0
(20.2)
(21.2)
(20.7)
(23.5)
(18.5)
(27.0)
(22.0)
(17.2)
(25.2)
(22,7)
(18.9)
(27.0)
(5.3)
(5.8)
(5-2)
(5.8)
(4.9)
(6.0)
(5.8)
(4.3)
(6.7)
(6.3)
(5.3)
(7.5)
37.8
42.0
33.6
201.0
206.2
195.6
15.0
8.3
21.6
110.0
104.9
116.7
10.5
11.5
9.4
55.1
57.1
53.1
4.0
2.2
5.8
30.4
29.2
31.6
(23.5)
(26.5)
(21.1)
(33.8)
(35.2)
(33.8)
(22.3)
(21.0)
(22.9)
(24.9) .
(24.7)
(25.2)
(6.6)
(7.1)
(6.5)
(6.3)
(6,8)
(5.3)
(6.0)
(5.6)
(6.1) :
(5.9)
(6.3)
(5.7)
PB= placebo baseline; CIT-A= acute citalopram treatment; CIT-E= the end of citalopram treatment;
PW= placebo withdrawal
Significant variations over time were only found for non-REMS stage 2 (min: Fi,«
= 8.8; P < 0.01; percent: Fw =20.3.; P < 0.01) and REMS (min: R,« = 32.1; P <
0.01; percent: FJ,« = 41.3.; P < 0.01) in the entire patient group. Post-hoc analy-
sis showed the following: the non-REMS stage 2 (min) result could be attributed
to a significant decrease in non-REMS 2 sleep during the withdrawal period
compared to baseline, acute treatment and the end of the citalopram treatment.
The non-REMS stage 2 (percent) result could be attributed to a significant incre-
ase of its percentage of total time asleep during acute citalopram treatment as
well as at the end of citalopram treatment compared to either baseline or
withdrawal. Both the REMS (min) and the REMS (percent) results could be attri-
buted to a significant decrease during acute citalopram treatment and at the end
of citalopram treatment compared to baseline as well as withdrawal. The REMS
(percent) result could further be attributed to a significant increase during
withdrawal compared to baseline. Neither the main effect on group (i.e. less
versus more improved) nor the interaction effect between group and time were
significant.
DISCUSSION
In this study a so-called A-B-A design was applied. Although the design does
not allow any conclusions on drug efficacy, the changes in sleep polygraphic
variables in relation to clinical changes can be studied adequately.
The main changes of sleep polygraphic variables in the entire patient group
were as follows. REMS (min and percent) was suppressed and REMS latency was
significantly increased, both initially and at the end of citalopram treatment.
These variables returned to baseline values 1 week after placebo withdrawal.
REMS (percent) further showed a significant rebound increase during withdra-
wal compared to baseline. No significant changes over the entire experimental
period were found for any sleep continuity variable. Because no significant
change was found in total time asleep, the decrease in REMS is independent from
changes in total time asleep. With respect to non-REMS an increase of stage 2
(percent) was observed both during acute treatment and at the end of citalop-
ram treatment. The amount of stage 2 in minutes decreased significantly during
withdrawal of citalopram. Summarizing, just like many other ADs citalopram
reduced REMS without affecting sleep continuity (Nicholson et al. 1989).
The less and more improved patients differed significantly with respect to
changes in subjective sleep quality and self-rated depressed mood.
Nevertheless, no significant differences between the two groups could be
demonstrated with respect to any of the sleep polygraphic variables. In particu-
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lar, the amount of both initial and sustained REMS suppression was not related
to clinical change. This does not support the hypothesis of Vogel et al. (1975;
1980) that REMS suppression is of central importance for the therapeutic pro-
cess. On the other hand, the hypothesis is also not disproved by the results,
because strong initial and sustained REMS suppression might be a necessary al-
though not sufficient component of the mechanism underlying treatment
response. Because no reduction of non-REMS duration was observed during tre-
atment, even less support was found for the proposal that non-REMS suppres-
sion would be essential for the beneficial effect of antidepressive treatment
(Borbely and Wirz-Justice 1982; Beersma and van den Hoofdakker 1992).
However, this conclusion is preliminary, since duration is not the only variable
by which non-REMS changes can be expressed. The power density of the sleep
EEG is another. Spectral analysis may reveal alterations in non-REMS which are
not recognized on the basis of visual scoring of the sleep EEG (Borbely et al.
1981). In a later spectral analysis of our sleep data the influence of citalopram
on non-REMS power density will be examined. .
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SUMMARY
According t o a recent hypothesis the therapeutic effects of antidepressants
might be related to acute or cumulative suppression of non-rapid eye move-
m e n t sleep (non-REMS) intensity. This intensity has been proposed to be
expressed in the EEG power density in non-REMS. In the present study the rela-
tionship was examined between the changes of EEG power density in non-REMS
and the changes in clinical state in 16 depressed patients during treatment with
citalopram, a highly specific serotonin uptake inhibitor. A one-week wash-out
period was followed by 1 week of placebo administration, a medication period
of 5 weeks, and a one-week placebo period. In order to minimize systematic
influences of sleep duration and non-REMS-REMS alterations, EEG power was
measured over the longest common amount of non-REMS stages 2, 3 & 4 (91.5
min). During the last treatment week and the week after withdrawal, a signifi-
cant decrease of EEG power as compared to baseline was found in the 8-9 Hz
frequency range. N o clear-cut change, however, was observed in the EEG
power of the delta frequency range (1-4 Hz), which is considered to be the
principle manifestation of non-REMS intensity. Furthermore, no relationship
between changes in EEG power density and changes in clinical state could be
demonstrated.
INTRODUCTION
The majority of antidepressant drugs (ADs) of all existing chemical classes sup-
press rapid eye movement sleep (REMS) (Vogel et al., 1990) and repeated selecti-
ve REMS deprivation over 3 weeks alleviates depression. Thus it has been hypo-
thesized that strong initial and sustained REMS suppression is an important fac-
tor in the mechanism underlying treatment response (Vogel et al., 1975; 1980).
However , no consistent relationships between decreases in REMS and the ameli-
ora t ion of depression have been demonstrated during treatment with ADs
(Riemann and Berger, 1990; Van Bemmel et al., 1992a). Hence, REMS suppres-
sion may be an impor t an t factor in the mechanism underlying treatment
response, it is not a sufficient factor.
The reports on the effects of ADs on non-REMS are inconsistent (Mendelson,
1989; Nicholson et al., 1989). It is not clear whether changes in non-REMS are
related to the improvement of depression. This may be due to the fact that the
quantification of non-REMS changes in terms of changes in duration is insuffi-
cient to detect such relationships. Borbely et al. (1981) have demonstrated that
during the night the power density of the sleep EEG undergoes a marked,
progressive decrease across stages. This probably reflects a non-REMS intensity
dimension which remains unrecognized by visual scoring of the sleep EEG.
One of the proposals specifying the link between non-REMS and depression,
the S-deficiency hypothesis, concerns this non-REMS intensity variable (Borbely
and Wirz-Justice, 1982; Borbely, 1987). According to this hypothesis the build-
up of process S (i.e. the build-up of the pressure for non-REMS) during waking
is impaired. Low levels of S cause depression, increased levels of S, e.g. by sleep
deprivation, cause normalization of mood. The level of S is considered to be
reflected in the EEG power density in non-REMS. Recently, it was shown in
healthy subjects that REMS deprivation by arousals resulted in a simultaneous
reduction of EEG power in non-REMS (Beersma et al., 1990). Moreover, Dijk et
al. (1991a) have demonstrated in chipmunks that the administration of the AD
clomipramine resulted not only in REMS suppression, but also in a decrease of
non-REMS power in the frequencies between 1.5 and 13.5 Hz. These findings
have led to the hypothesis that acute or cumulative suppression of non-REMS
intensity rather than suppression of REMS is a key factor in mechanisms under-
lying improvement (Beersma and Van den Hoofdakker, 1992). Summarizing,
ADs therefore might be effective because they suppress non-REMS intensity.
In the present study we examine this possibility by investigating the rela-
tionships between changes in non-REMS power and changes in clinical state in
patients during treatment with the AD citalopram. This drug has a number of
advantages. It is one of the most selective serotonin (5-HT) uptake inhibitors
currently available. An intensification of 5-HT neurotransmission has been
associated with recovery of depression (Blier et al.,, 1987), while the 5-HT pro-
perties of ADs seem to play an important role in mediating the REMS inhibiting
effects (Nicholson et al., 1989). The metabolites of citalopram are also 5-HT
specific (Hyttel, 1982). Citalopram appears to have little effect on noradrener-
gic or dopaminergic systems, and it is practically devoid of anticholinergic and
antihistaminergic properties. The efficacy of citalopram after 6 weeks of treat-
ment is similar to that of reference ADs, in particular tricyclics (Bech and
Cialdella, 1992). For humans no sleep data have been published but the drug
has been shown to suppress REMS and to promote slow wave sleep in cats
(Hilakivi et al., 1987).
In summary, citalopram was considered to be a rather adequate pharmacolo-
gical probe in the study on the role of non-REMS intensity changes in the
mechanisms underlying drug induced antidepressant effects.
85
MATERIALS AND METHODS
Study design
After a one week wash-out period there were three consecutive treatment
periods encompassing a total of seven weeks. In week 1 a placebo was adminis-
tered; in weeks 2-6 the subjects were treated with citalopram (week 2: 20
mg/day; weeks 3-6: 40 mg/daily at 6:00 p.m.); in week 7 citalopram was abrupt-
ly discontinued and substituted by a placebo. The administration of the place-
bo and citalopram was single blind. Subjects were informed, however, that
placebo treatment could occur.
Subjects
The participants were outpatients suffering from major depression, single or
recurrent [DSM-III-R (APA, 1987) codes 296.2 and 296.3], including insomnia
(DSM-III-R code 307.42). Subjects were only included if two psychiatrists
agreed on the diagnosis. A score of 20 or higher on the Hamilton Rating Scale
for Depression (HRSD, 17 items; Hamilton 1967) was required. Patients with a
current history of sleep disorders such as sleep apnea or nocturnal myoclonus
were excluded on the basis of a medical interview. The results of physical exa-
mination, blood chemistry and haematology were within the normal range.
Subjects were free of psychoactive medication for at least one week before
placebo week 1 and their eligibility was decided after this wash-out period. At
the end of week 1 (placebo-baseline) only subjects whose HRSD score was 20 or
higher and those with a decrease of no more than 30 % compared to the initial
HRSD score after wash-out were included. During the study alcohol consump-
tion, consumption of beverages containing caffeine (from lunch time), comedi-
cation, and napping were not allowed. The compliance to the instruction not to
nap was not controlled for by objective measurements. The protocol was revie-
wed and approved by the institutional Ethics Review Committee and the sub-
jects gave informed consent.
Measurements
Depression
The severity of depression of the previous week was assessed at the end of each
experimental week by means of the HRSD, rated by two psychiatrists.
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Sleep EEGs of each subject were recorded between 11:00 p.m. and 7:00 a.m. for
seven nights in our sleep laboratory. The sleep recordings were scheduled in
such a way as to enable evaluation of the baseline characteristics of sleep (2
consecutive nights at the end of Week 1), the acute effects of citalopram on
sleep (the night after the first citalopram treatment day), the effects at the end
of the citalopram treatment period (2 consecutive nights at the end of Week 6),
and the effects of one-week placebo-withdrawal (2 consecutive nights at the
end of Week 7). The first baseline night was preceded by an adaptation night.
The recordings were obtained at a paper speed of 10 mm/s from standard
leads: two EOGs, two EEGs (C3-A2 and C4-A1) and a submental EMG. The time
constants for the EOG and EEG recordings were 0.3 s; the high frequency cut-off
was 35 Hz. All signals were stored on magnetic tape for off-line analyses.
Measures
For each subject the average of the two HRSD ratings during each experimental
week was used as an index of the severity of depression. For each assessment
the rank correlations between the two HRSD ratings obtained in all patients
were calculated. The resulting 7 correlation values showed a range between 0,90
and 0.96. This indicates a close overall correspondence { > 80 %) between the
two HRSD raters with respect to the assessment of the severity of depression.
The average HRSD score at the end of week 6, relative to that of placebo-base-
line (week 1), was taken as a measure for the clinical change at the end of the 5-
week citalopram treatment,
S/ee/? recon/iVzgs
These were analysed visually in successive 30-s epochs according to the scoring
rules of Rechtschaffen and Kales (1968). The following additional variables
were assessed: sleep onset: the first epoch, after "lights out", of stages 2, 3, 4 or
REMS, followed by at least 10 min of sleep interrupted by no more than 2 min of
stage 1 or wakefulness; end of sleep: the last epoch of stages 2,3,4 or REMS, pre-
ceded by at least 10 min of sleep interrupted by no more than 2 min of stage 1
or wakefulness.
One EEG signal [i.e. in each subject obtained from the same lead in all condi-
tions (C3-A2 or C4-A1)] was low-pass filtered for spectral analysis at 25 Hz (24
dB/oct) and subsequently digitized at 64 samples/s. Digitized data were proces-
sed by a fast Fourier transform routine. Power spectra were calculated over 4-s
intervals from 0.75-15 Hz in 0.25 Hz bins, by applying a rectangular window.
The 0.25 bins were condensed into 1 Hz wide frequency bins. Bins will be
referred to by mentioning their upper limit, so power density in the 1 Hz bin is
the sum of the power density of 0.75 and 1 Hz; power density in the 2 Hz bin is
the sum of the power density of 1.25,1.50,1.75 and 2 Hz etc. To obtain a reso-
lution of 30-s, power values of 7.5 adjacent 4-s epochs were summed for each
frequency bin thus calculated. Visual scores of the same 30-s epochs were syn-
chronized with the series of power spectral epochs.
The influence of citalopram on non-REMS power was analyzed on the basis of
the longest common amount of non-REMS stages 2,3 & 4, accumulated from
sleep onset onwards (see Discussion). 30-s epochs of non-REMS stages 2, 3 & 4
containing EEG-artefacts [mean: 6.8 % (SD = 3.1) of all non-REMS 2, 3 & 4
epochs] were omit ted from further spectral analysis, on the basis of visual
inspection of the original tracings.
Since the absolute values of the power densities of the higher frequencies are
several orders of magnitude lower than those of the lower frequencies and since
the interindividual variation is considerable, absolute values are not very suita-
ble for a visualization of changes in power spectra (Dijk et al.,1989). Therefore,
in the figures power values of each subject were expressed relative to power
values in baseline, which were taken as 100 %.
T o monitor changes in sleep over the four experimental periods the following
variables were used: the averages of the sleep data of the two consecutive sleep
recordings at the end of week 1 (= placebo baseline), of those at the end of
week 6 (= end of citalopram treatment), and of those at the end of week 7 (=
placebo withdrawal); the evaluation of the acute treatment effects on sleep is
based on the data of the night after the first citalopram treatment day.
Analyses
MANOVA for repeated measures (O'Brien and Kister Kaiser, 1985) was applied
over the four experimental periods. The Newman-Keuls (NK) post-hoc proce-
dure was used to detect where significant results were located. With respect to
mood change a rank order of the patients was made on the basis of the differen-
ce between the HRSD scores at the end of the citalopram treatment period and
those in baseline. Subsequently, the entire patient group was divided into two:
a group with relatively small changes in HRSD scores, the less improved group,
and a second group with relatively large changes in HRSD scores, the more
improved group. Comparisons between the two groups were made by means
of MANOVA for repeated measures. Because of the skewed distribution of the
results of the sleep EEG power variables log-transformed values were used for
statistical tests. P values < 0.05 were accepted as significant.
RESULTS
Table 1 shows the biographic and clinical characteristics of the 16 patients who
participated in the study. The less and more improved groups did not differ
significantly with respect to sex and age.
Table 1. Sex (F= female; M= male), age, HRSD baseline scores, and change in HRSD scores at the end
of citalopram treatment expressed as deviation from the baseline value
Sex
M
F
M
M
M
M
F
F
Less improved patients
Age
51
39
58
54
52
50
35
37
HRSD
baseline
score
26.0
32.0
28.0
28.5
24.0
29.0
32.0
24.0
HRSD
change
(%)
0
0
12
20
39
48
53
54
Sex
M
F
1-
!•
M
M
M
F
More i
Age
45
26
46
24
47
30
47
29
mproved patients
HRSD
baseline
score
22.0
24.0
30.0
23.5
31,0
24.0
22.0
21.0
HRSD
change
(%)
56
57
60
62
71
75
82
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Depression
Over the seven experimental weeks of the protocol the HRSD of the entire
group showed a significant variation over time (FM< = 21.5; P < 0.01). This
result could be attributed to a significant improvement of depressive mood
during the period between the 2nd and the 6th week compared to baseline as
well as to the 1st citalopram treatment week. The less and more improved
groups did not differ significantly with respect to HRSD baseline scores (Fu«
=3.5;P = 0.09)(Table2). . . . . • • : . , .-...-: . . . , . . ;
Table 2. Severity of depression (liRSD). Mean values and standard deviations during the 7 experi-
mental weeks of the entire g roup (All), the less improved (u), and the more improved (Ml) patients
WEEKS
PB
CIT-1
ClT-2
crr-3
CIT-4
CIT-5
PW
All
26.3
21.8
19.5
18.4
16.9
13.8
14.1
(n=16)
(3.7)
(6.5)
(6.4)
(7.3)
(7.8)
(6.9)
(6.8)
LI
27.9
25.9
24.3
22.1
21.4
18.9
19.2
(n=8)
(3.1)
(4.2)
(4.1)
(5.1)
(5.0)
(6.1)
(5.2)
Ml
24.7
16.7
14.6
14.7
12.4
8.6
8.9
(n=8)
(3.8)
(5.1)
(4.6)
(7.5)
(5.2)
(2.3)
(3.4)
= placebo baseline; CIT-1 to CIT-5 = the 5 citalopram treatment weeks; PW = placebo withdrawal
Sleep stages
Table 3 shows the mean values, the standard deviations, and the corresponding
statistics of the sleep stages.
Compared to baseline non-REMS was not significantly affected during citalo-
pram treatment. O n e week after withdrawal the amount of non-REMS was sig-
nificantly decreased compared to baseline and to both the acute treatment
period and the end of the treatment. Citalopram suppressed REMS significantly
both during the acute treatment period and at the end of the treatment, compa-
red to both baseline and withdrawal. No significant variation over the four
experimental periods was found for total time awake and stage 1. The less and
more improved patients did not differ significantly for any of the sleep varia-
bles.
Power spectra in non-REMS
The longest common amount of non-REMS stages 2,3 & 4 turned out to be 91.5
minutes. Figure 1 shows the geometric means, and the corresponding statistics,
for the power spectra during 91.5 rain of non-REMS (the power spectra of each
subject separately are shown in Appendix).
Within these 91.5 min of non-REMS MANOVA over the 4 experimental periods
provided significant results for the EEG power of the 4 to 9 Hz bins and for the
13 Hz bin. The post-hoc procedure failed to show where overall differences
were located with respect to the 5, 6 and 13 Hz bins. At the end of the treat-
ment and during withdrawal the EEG power of the 8 and 9 Hz bins was signifi-
cantly decreased compared to baseline. The EEG power of the 4 and 7 Hz bins
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Table 3. The amounts in minutes between sleep onset and end of sleep of non-REMS stages 2,3 & 4
(NREMS); RliMS; total time awake (AWAKE); and non-REMS stage 1 (NREMS-1). Mean values and stan-
dard deviations of the entire patient group (Ail) (n=16), the less improved (LI) (n=8) and the more
improved (Ml) (n=8) patients
Sleep
stage
NREMS
(min)
REMS
(mm)
AWAKE
(min)
NREMS-1
(min)
Group
All
LI
MI
All
LI
Ml
All
LI
MI
All
LI
MI
n
PB
253.1
(35.6)
255.1
(22.6)
251.2
(46.9)
97.2
(22.0)
108,5
(22.2)
85.9
(16.0)
34.1
(22.4)
26.7
(9.8)
41.5
(29.2)
36.4
(28.1)
36.4
(23.4)
36.4
(33.7)
C1T-A
• 272.9
(58.6)
273.1
(42.2)
272.7
(74.6)
47.7
(26.9)
48.1
(25.3)
47.3
(30.2)
47.3
(37.5)
57.6
(38.0)
37.1
(36.4)
40.3
(23.0)
42.1
(14.9)
38.5
(30.1)
crr-E
267.3
(23.4)
267.4
(23.2)
267.2
(25.3)
62.0
(22.7)
59.1
(18.9)
64.8
(27.0)
35.1
(16.7)
40.6
(14.9)
29.7
(17.6)
49.5
(20.2)
49.3
(21.2)
49.7
(20.7)
PVf
216.0
(35.4)
214.6
(30.8)
217.2
(41.7)
110.8
(24.9)
104.9
(24.7)
116.7
(25.2)
38.9
(29.6)
45.0
(39.7)
32.8
(14.8)
37.8
(23.5)
42.0
(26.5)
33.6
(21.1)
PB = placebo baseline; CIT-A = acute citalopram treatment; CIT-E = end of citalopram treatment; PW
= placebo withdrawal. Significant MANOVAs over the 4 experimental periods: (*) Fi,« = 10.2 (P <
0.01); (**) FJ,« = 32.1 (P < 0.01), Neither the main effect on group (i.e. less versus more improved)
nor the interaction effect between group and time were significant for any of the sleep variables
was significantly decreased during withdrawal compared to baseline.
On inspection, the effect of citalopram on EEG power seemed to be more pro-
nounced in the less improved patient group (B) than in the more improved
group (C). However, these groups did not differ significantly for the EEG
power values in any bin. As the less improved patients were on average about
10 years older than the more improved patients and because on inspection the
effects of citalopram on EEG power seemed to differ between the two groups,
Figure 1. Power spectra of 91.5 min non-REMS, relative to power spectra of baseline (= 100 %).
Geometric means of the entire patient group (n=16) (A), the less improved (n=8) (B), and the more
improved (n=8) (C) groups separately. Power densities are plotted at the upper bounderies of the
frequency bins. CIT-A = acute citsdopram treatment; CIT-E = end of citalopram treatment; PW =
placebo withdrawal. The frequency ranges in which the values varied significantly (p < 0.05 ;
MANOVA) over the 4 experimental periods are indicated by black bars above the abscissa of A.
Neither the main effect on group (i.e. less versus more improved; B and C) nor the interaction
effect between group and time were significant for the EEG power values in any 1 Hz bin
NREM POWER (%) „ NREM POWER (%)
-CIT-A
» * t * » » ti 12 « 14 tt
FREQUENCY (Hz> X) It 12 19 M WFREQUENCY (Hz)
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the possible relationship between age and the relative power values in the 4-9
Hz frequency range was investigated. Only low and non-significant rank corre-
lations could be found [at the end of the citalopram treatment: rho = - 0.44 (P =
0.10); after one week of withdrawal: rho= - 0.37 (P = 0.16)].
DISCUSSION
Before we discuss the results of this study, the details of our spectral analysis
will be argued. The analysis of the effects of particular treatments on EEG power
production offers some serious pitfalls. Usually, EEG power is high during the
first non-REMS episode and decreases during the next episodes (Borbely et al.,
1981; Achermann and Borbely, 1987; Dijk et al., 1991b). Furthermore, EEG
power production waxes and wanes with the non-REMS-REMS alternation, beco-
ming very low in REMS. The best simple and direct way to compare power pro-
duction within and between subjects is to compare the powers produced in the
longest common amount of non-REMS. The following examples may explain
why this is a better variable than, e.g., average EEG power over total non-REMS
time. Suppose that a particular treatment does not have any effects on non-
REMS power or sleep duration, but it does affect intermittent waking or REMS.
The average EEG power over total non-REMS time will change then according to
the changes in time spent in REMS or in intermittent waking. Using this variable
would thus lead to the false interpretation that the treatment interfered with
non-REMS power production. Another example; suppose that the treatment
produces a change in sleep duration. Since EEG power is usually low at the end
of sleep, longer sleep will lead to a lower average EEG power, even if power pro-
duction is not affected by the treatment. Again, reliance on this variable would
result in a false interpretation of the real effects of the intervention.
In an attempt to avoid the aforementioned problem, some authors (Reynolds
et al., 1991) have chosen to use the power production in the first non-REMS-
REMS cycle as a critical variable. However, this leads to another problem. In the
course of a non-REMS episode EEG power increases until it reaches a plateau
value, followed by a rather steep decline shortly before REMS (Achermann and
Borbely, 1990). If a treatment merely lengthens REMS latency, the EEG power
plateau will last longer, and the average level of EEG power will increase.
Average EEG power production would then erroneously suggest that the treat-
ment interferes directly with non-REMS power production per se. Similar
remarks can be made with respect to the study of Kupfer et al. (1989). In this
study non-REMS power during the first 100 min of baseline sleep was compared
with power during the same interval of sleep after a 'loading dose' of clomipra-
mine. However, the duration of REMS and wakefulness within the lQQ-min
intervals would be expected to be very different under the two conditions. No
data regarding these critical issues are provided by the authors.
Although the aforementioned pitfalls were avoided in our spectral analysis,
some interpretation problems remain. The frequency of sleep interruptions is
also of influence upon non-REMS power. An interruption leads to reduced
power values, followed by a relaxation period in which power gradually increa-
ses again. It cannot be excluded that changes in sleep continuity have influen-
ced the power spectra. Knowledge of the dynamics of these processes is not yet
sufficient to es t imate the consequences of these effects (Achermann and
Borbely, 1987). Nevertheless, the absence of significant variations over the
experimental periods in total intermittent wakefulness and stage 1 sleep sug-
gests that it is reasonable to assume that changes in sleep continuity were of
little influence for the results of our analysis.
The present study shows that citalopram suppresses EEG power of non-REMS
mainly in the 8-9 Hz range and that this effect persists during withdrawal. In addi-
tion, MANOVA over the four experimental periods provided significant differences
in the EEG power values of the 4 to 7 Hz bins and of the 13 Hz bin. By post-hoc
analysis these differences could not be attributed to an obvious decrease of EEG
power during citalopram treatment. Therefore, no clear-cut decrease was obser-
ved in the EEG power of the delta frequency range (1-4 Hz), which is considered
to be the principle manifestation of non-REMS intensity (Borbely et al, 1981).
The persistence of the suppression of the 8-9 Hz activity during withdrawal
contrasts with the immediate rebound of REMS. Interestingly, there was no
worsening of clinical state during the one week withdrawal period. Hence, the
only relationship between sleep physiology and improvement is found in the
similarity of the overall time courses of mood and of the 8-9 Hz range of non-
REMS. Unfortunately, in spite of this overall similarity, no significant difference
was found between the less and more improved patient groups for EEG power
values in any 1 Hz bin.
In an earlier study (Van Bemmel et al., 1992b) in a sample of eight depressed
patients treated with the AD trazodone a similar pattern emerged. Here the cli-
nical response pat tern showed considerable similarity to that of the spectral
power changes in the 13-14 Hz band. But at the level of individual changes no
clear-cut relationships were observed between magnitude of mood changes and
the amount of change in this EEG frequency band.
In summary, no relationships were found between clinical change and chan-
ges in power densities, either in the present citalopram study or in the earlier
trazodone study. Moreover, the drugs turned out to affect EEG power produc-
tion very differently: in the 8-9 Hz and the 13-14 Hz range respectively. The
data do not support the hypothesis that suppression of non-REMS intensity as
expressed in the 1-4 Hz range reflects a common pathway in the antidepressant
effects of pharmacological manipulations.
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CHAPTER 6
Epilogue
/or t/?e J&on'zon wowW/^roi'aWj ^e a ^wa/^of'wfing /)/are awj'Wd^.
(WONDERFUL LIFE, Stephen Jay Gould)
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In the preceding chapters the importance of the ADs-induced sleep changes for
the alleviation of depression was studied. The literature shows that the best
documented effect of most efficacious ADs on sleep polygraphic variables in
man is REMS suppression, irrespective of their chemical classes. The few reports
on the therapeutic significance of the amount of REMS change induced by ADs
are inconsistent. ;
The results of the clinical sleep studies of this thesis could not confirm the
hypothesis of Vogel (1983) which offers an explanation for the therapeutic role
of REMS suppress ion. The main results of the studies on sleep polygraphic
variables (chapters 2 and 4) indicate that the ADs trazodone and citalopram
both produce REMS suppression and lenghtening of REMS latency, whereas no
significant changes were found in sleep continuity variables. The observed sig-
nificant suppression of REMS during the treatment periods in both studies and
its return to baseline values after one-week withdrawal of the drugs, indicate
that the ADs produce a sustained REMS pressure during treatment. However, in
both studies, REMS suppression was clearly not related to the amelioration of
the clinical state. This does not support, therefore, the hypothesis of Vogel
(1983) that strong initial and sustained REMS suppression is of central importan-
ce for the therapeutic process. On the other hand, the hypothesis is also not
disproved by the results, because strong initial and sustained REMS suppression
(i.e. REMS pressure) might be a prerequisite for the initiation of other, yet un-
known, processes which are important for the antidepressant action.
The hypothesis of McCarley (1982) of a common pathophysiological mecha-
nism of REMS disturbance and depression was not tested directly in the present
studies. According to this hypothesis a depressive state is supposed to be the
expression of a relatively decreased monoaminergic (i.e. serotonergic & norad-
renergic) activity in combination with a relatively increased acetylcholinergic
activity. Drugs which modify transmission in these systems upset the balance
of activities which are supposed to be essential to the appearance of REMS, and
the probabi l i ty of entering REMS is reduced (Nicholson and Pascoe, 1991).
Consequently, such drugs would also have antidepressant properties. Because
the drugs under s tudy (i.e. trazodone and citalopram) activate the serotonergic
system more or less specifically (Johnson, 1991) and during the treatments
REMS suppression was found, it can be stated that the results at least do not
refute this prediction derived from McCarley's hypothesis.
In spite of this, our results are in accordance with the observation that drugs
which alleviate depression appear to be associated in general with a marked
r e d u c t i o n of REMS, w i th o r without sleep reduction (Vogel et al., 1990;
Nicholson and Pascoe, 1991). The question whether such a polysomnographic
profile of ADs is of clinical significance remains difficult to answer.
Recent fundamental sleep research has provided the first quantitative hypo-
theses (Borbely and Wirz-Justice, 1982; Borbely, 1987; Beersma and van den
Hoofdakker, 1992) on the therapeutic significance of non-REMS intensity chan-
ges produced by ADs. According to these hypotheses the antidepressant action
of ADs is due to non-REMS intensity suppression. In two of our studies (chap-
ters 3 and 5) this prediction was tested by means of spectral analysis of the
sleep EEC No clear-cut relationship between suppression of EEG power density
in non-REMS, especially in the delta frequency range (i.e. SWA), and clinical
change could be demonstrated. ., • .
Although they are not in agreement with the prediction of the hypotheses, a
definite interpretation of our findings, in terms of the hypotheses, must await
the elucidation of several fundamental aspects of sleep regulation and their
modification by ADs. It can not be excluded that sleep disruptions and changes
in the amount and distribution of REMS have played a role in the changes of
non-REMS power in our data (Achermann et al., 1990). More knowledge, there-
fore, about the interference with EEG power production by sleep disruptions or
REMS changes is needed to assess the contribution of ADs to non-REMS power
production. Quantitative data on the influence of REMS changes on non-REMS
power will also enable an evaluation of the effects of ADs on the process of reci-
procal interaction between REMS and non-REMS, in terms of the hypothesis of
McCarley (1982; see also Massaquoi and McCarley, 1992). To this end studies
on the effects of ADs on the sleep EEG in healthy subjects, with non-disturbed
baseline sleep are necessary.
At the same time, an interpretation of the observed AD-induced EEG power
changes in terms of non-REMS regulatory processes is not quite possible.
Clearly, our results obtained after the 5-week treatment periods are very diffe-
rent from the characteristic short-term changes of EEG power after non-phar-
macological manipulations of non-REMS in healthy subjects. The effects of tra-
zodone were mainly located in the 13-14 Hz range, those of citalopram in the 8-
9 Hz range. Sleep manipulations, such as sleep deprivation and REMS depriva-
tion, typically result in changes in the 1-7 Hz range during non-REMS, which
changes are considered to reflect non-REMS homeostasis, i.e. process S (see
review by Borbely and Achermann, 1992). Because in our studies no significant
change was found in the lower EEG frequencies, this would suggest that ADs act
merely on EEG generating mechanisms without interfering with non-REMS
regulatory mechanisms (Dijk et al., 1991). Alternatively, ADs may affect the
sleep EEG directly as well as these sleep regulatory processes. A distinction
between these possibilities could be made by means of sleep deprivation, which
activates predictively non-REMS regulatory processes. In further studies on the
effects of ADs on sleep, therefore, the EEG should be recorded before and after
sleep deprivation under placebo as well as during the administration of an AD.
Finally, the interpretation of AD-induced EEG spectral patterns in terms of
sleep pharmacology needs more research. Our results suggest that ADs do not
all produce similar. EEG spectral response patterns. This might be due to diffe-
rences in pharmacological actions among the various ADs. In support of this
notion, further clinical research to identify and to interprete EEG response pat-
terns induced by the various ADs is needed. In this context a better understan-
ding of the neu'robiological events underlying the EEG generating mechanisms
is also warranted (see review by Steriade et al., 1990). At the moment the neu-
rophysiological and neurochemical origins of specific EEG frequency bands,
and their functional significance are largely unknown (Borbely, 1986; Borbely
and Achermann, 1992). Recently, two animal studies have provided the first
indications of the origin of SWA. Steriade et al. (1991) have reported that in the
cat hyperpolarized thalamic neurons exhibit fluctuations of membrane poten-
tials in the slow wave frequency range. These fluctuations might be manifesta-
t ions of the mechanisms underlying sleep homeostasis at the cellular level
(Borbely and Achermann, 1992). Lancel et al. (1992) observed enhanced SWA
within non-REMS in the cortical and subcortical EEG of the cat after sleep depri-
vation. These data may indicate that SWA reflects a recovery process in cortical
and subcortical structures. Similar animal studies in which the influence of ADs
will be examined, may provide relevant knowledge for pharmacological sleep
research in depressives.
Summarizing, knowledge from fundamental sleep research has inspired the cli-
nical studies of this thesis. An attempt has been made to quantitatively relate
AD-induced changes in sleep to accompanying clinical changes. Neither our
studies on the changes in sleep polygraphic variables, nor those on the changes
in non-REMS power produced clear evidence of involvement of REMS or non-
REMS intensity in the mechanisms underlying clinical change. The observed EEG
spectral response patterns during treatment with the studied ADs were clearly
different from the changes in EEG power induced by non-pharmacological
manipulations of sleep. These results raise different questions. In order to inter-
prete the effects of ADs on non-REMS regulation in terms of sleep physiological
processes more fundamental sleep research is necessary. Also more comparati-
ve studies of ADs with similar therapeutic effects but different pharmacological
profiles are needed in both healthy and depressed subjects to further quantify
the impact of non-REMS modification in the recovery of depression and to dif-
ferentiate between pharmacological and sleep related aspects. An answer to the
important question whether ADs with the same pharmacological specificity will
produce similar changes of sleep EEG power spectra can also be expected from
further studies. As in the research on hypnotic drugs (Borbely et al., 1991) also
in clinical sleep research with ADs spectral analysis of the sleep EEG will become
increasingly important for interpreting the effects of ADs on sleep in depressi-
ves.
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The near future will show whether the so far inspiring cross-fertilization
between clinical and fundamental sleep research will produce more insight into
the link between sleep and depression. In this respect a further contribution to
fundamental knowledge can be expected from sleep research with ADs.
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SUMMARY
The assumption that sleep dysregulation is more than a mere epiphenomenon
of depression is based on several observations. Firstly, sleep complaints have
been considered as cardinal symptoms of depression for as long as this disorder
has been recognized. Approximately 90 % of the patients suffering from a
major depressive episode report complaints of severe insomnia. Such sleep dis-
turbances are objectively substantiated by means of polysomnography.
Secondly, it is now widely recognized that a number of sleep manipulations,
particularly sleep deprivation, can alleviate symptoms of depression. Thirdly,
antidepressant drugs (ADs) bring about remarkable changes in sleep polygra-
phic variables. Changes in sleep physiological processes might therefore be inti-
mately involved in the pathogenesis and recovery of depression. The major
theme of this thesis was to examine the influence of ADs on sleep in relation to
the changes in clinical state during treatment.
In chapter 1 the literature on the effects of ADs on sleep polygraphic variables
was reviewed against the background of four existing hypotheses concerning
the relationship between sleep and depression. The best documented effect of
most ADs, irrespective of their chemical classes, on sleep polygraphic variables
in man are reduction of the amount of rapid eye movement sleep (REMS) and
lengthening of REMS latency, while a REMS rebound is observed during withdra-
wal. Both the REMS pressure hypothesis and the hypothesis of a common
mechanism controlling both REMS and depression are consistent with this
general finding. They both focus on the role of REMS: suppression of REMS
during treatment with ADs would be of importance for the improvement of
depression. Two hypotheses (i.e. the S-deficiency and non-REMS hypotheses)
provide an explanation in terms of non-REMS regulation and predict that an
acute or cumulative suppression of non-REMS intensity' is responsiblei for the
therapeutic effects of ADs. They are indirectly related to REMS suppression
because REMS suppression has been shown to reduce non-REMS intensity.
In chapters 2, 3, 4 and 5 the data collected during two research projects in
subjects with a major depression and insomnia were presented and discussed:
the first project with the AD trazodone and the second with the AD citalopram.
In both projects the same single blind design was used: a one-week wash-out
period was followed by 1 week of placebo administration, a medication period
' Non-REMS intensity is considered to be expressed by the EEG power density of mainly the lower
frequencies (1-4 Hz) during non-REMS, and can be measured continuously and quantitatively by
spectral analysis of the sleep EEG. This variable plays an important role in a recent model, which
offers an explanation of sleep regulation in terms of an interaction between a homeostatic and a
circadian process. This model, i.e. the two-process model of sleep regulation, has proven to be
successful in demonstrating the homeostatic character of non-REMS intensity.
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of 5 weeks, and a one-week placebo period. The sleep results were either obtai-
ned by polysomnography (chapters 2 and 4) or by spectral analysis of the EEC
during non-REMS (chapters 3 and 5).
In chapter 2 the study on the effects of the AD trazodone on clinical state and
on sleep polygraphic variables in eight outpatients with a major depressive dis-
order was presented. Earlier reports on trazodone seem to question the signifi-
cance of RF.MS suppression in the pharmacological alleviation of depression. In
fact it was suggested that slow wave sleep (SWS) increase and amelioration of
sleep continuity rather than REMS decrease would be of therapeutical significan-
ce. However, in our study trazodone did not influence sleep continuity (i.e.,
sleep latency, sleep period, total time asleep, total time awake, and sleep effi-
ciency) and SWS, but did suppress REMS significantly. A significant increase of
REMS latency was also found. The REMS variables returned to baseline values
after one week placebo-withdrawal. No clear-cut relationship, however, was
found between clinical response and changes in REMS parameters.
In chapter 3 the effects of trazodone on non-REMS intensity were examined.
The EEG power spectra of the entire patient group showed a significant decrea-
se of the power in the 13 and 14 Hz bins during trazodone treatment and a sig-
nificant decrease in the 1 Hz bin one week after withdrawal of this drug. Upon
inspection, four out of five clinical responders demonstrated a suppression of
EEG power of the lower frequencies during and after trazodone treatment. This
shows some consistency with the recent hypothesis on the role of non-REMS
intensity suppression in the improvement of depression.
In chapter 4 the effects of the AD citalopram, a highly specific serotonin upta-
ke inhibitor, on sleep polygraphic variables and clinical state in 16 outpatients
with a major depression were presented. Compared to the eight "less impro-
ved" patients the eight "more improved" patients reported an improvement of
both subjective sleep quality and self-rated mood. Citalopram did not influence
sleep continuity, but did increase non-REMS stage 2 (percentage) significantly.
Both during acute treatment and at the end of citalopram treatment a signifi-
cant suppression of REMS was found. A significant lengthening of REMS latency
was also found. The REMS variables returned to baseline values after one week
placebo-withdrawal. However, the "less" and "more improved" patients did
not differ significantly with respect to any sleep polygraphic variable.
In chapter 5 the effects of citalopram on non-REMS intensity were presented.
At the end of the citalopram treatment and one week after withdrawal, a signi-
ficant decrease of EEG power mainly in the 8-9 Hz frequency range compared
both to baseline and acute treatment in the entire patient group was found. No
obvious change, however, was observed in the EEG power of the delta frequen-
cy range (1-4 Hz), which is considered to be the principle manifestation of non-
REMS intensity. Furthermore, no relationship between changes in EEG power
density and changes in clinical state could be demonstrated.
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In chapter 6 it was concluded that the hypotheses which consider REMS sup-
pression of therapeutic importance are not confirmed in this thesis.
Nevertheless REMS suppression might still be a prerequisite for the initiation of
other, yet unknown, processes which are of importance for the improvement of
depression.
Results from fundamental sleep research based on the two- process model of
sleep regulation had inspired the EEG spectral studies of this thesis. The studies
did not provide results supporting the hypotheses that suppression of non-
REMS intensity is a key factor in the action of ADs. The results make clear that
further fundamental and clinical sleep research is necessary. More knowledge is
needed about the interference of sleep EEG power production by sleep disrup-
tions or REMS changes and the influence of ADs on sleep homeostatic regulatory
processes. Furthermore, there is a need for a better understanding of the neuro-
biological origins of the EEG spectral response patterns produced by ADs.
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SAMENVATTING
De veronderstelling dat de relatie tussen stoornissen van de slaap en depressie
van betekenis is voor het ontstaan en het herstel van depressie, is gebaseerd op
verschillende waarnemingen. Ten eerste: van oudsher worden slaapklachten
beschouwd als kenmerkende symptomen van depressie. Ongeveer 90 % van de
mensen die een episode met een depressie in engere zin (volgens DSM-III-R cri-
teria) doormaakt, vermeldt ernstige slapeloosheidsklachten. Dergelijke klachten
zijn objectief aantoonbaar middels polygrafisch onderzoek van de slaap (d.w.z.
tijdens de slaap continue geregistreerde EEG, EOG en EMG). Ten tweede: inmid-
dels staat vast dat bij ongeveer de helft van deze mensen manipulaties van de
slaap, zoals totale slaapdeprivatie, tijdelijk een gunstige verandering van de
depressie teweeg kunnen brengen. Ten derde: antidepressieve medicatie blijkt
op een opmerkelijke manier de slaap te kunnen bei'nvloeden. Dus veranderin-
gen in de slaapfysiologie zouden van betekenis kunnen zijn voor het ontstaan
en het herstel van de depressie. In dit proefschrift werd nagegaan wat de
samenhang zou kunnen zijn tussen veranderingen van de slaap en van depres-
sieve symptomatologie tijdens een behandeling met een antidepressivum.
In Hoofdstuk 1 werd de literatuur betreffende de effecten van antidepressiva
op de slaap besproken, tegen de achtergrond van vier hypothesen m.b.t. de
relatie tussen slaap en depressie. De meeste antidepressiva bleken, onafhanke-
lijk van hun farmacologisch profiel, de snelle oogbewegingen siaap (rapid eye
movement slaap of REMS) op een opmerkelijke manier te bei'nvloeden: de hoe-
veelheid REMS wordt onderdrukt en de REMS-latentietijd (d.w.z. de tijd tussen
het begin van de slaap en het eerste optreden van REMS) wordt verlengd. Het
stoppen van een behandeling met een antidepressivum veroorzaakt meestal een
terugkeer van deze REMS-waarden naar het nivo van voor de behandeling,
Zowel de REMS-druk (REMS pressure) hypothese, als de hypothese van een
gemeenschappelijk controlemechanisme van REMS en depressie (a common con-
trol mechanism of both REMS and depression) zijn consistent met deze bevin-
dingen. Ze leggen vooral de nadruk op de rol van de REMS: een onderdrukking
van de REMS gaat gepaard met een herstel van de depressie. Twee hypothesen
(de S-deficientie en de niet-REMS hypothesen) bieden een verklaring in terrnen
van de regulatie van de niet-REMS en voorspellen dat acute of cumuiatieve
onderdrukking van de niet-REMS-intensiteit* verantwoordelijk is voor de thera-
' De intensiteit van de niet-REMS (non-REMS intensity) zou tot uiting komcn in de cnergie van voor-
al de lagere frequenties (1-4 Hz) van het EEG tijdens de niet-REMS. Deze kan continue en kwantita-
tief gemeten worden middels spectraal analyse van het slaap EEG. Deze variabele speelt een
belangrijke rol in een recent model dat een verklaring beoogt van dc slaap regulatie in tcrmen van
ecu imeractie tussen een homeostatisch en een circadiaan proces. Dit model (the two-process
model of sleep regulation) is tot dusverre vooral succesvol gebleken in het aantonen van het
homeostatisch karakter van de intensiteit van de niet-REMS.
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peutische effecten van antidepressiva. Een onderdrukking van deze EEG-inten-
siteit zou verantwoordelijk zijn voor het herstel van de depressieve toestand.
Ind i rek t w o r d t een relatie gelegd met REMS-onderdrukking, omdat REMS-
onderdrukking een afname van de niet-REMS-intensiteit te zien geeft.
In de H o o f d s t u k k e n 2, 3, 4 en 5 werden de resultaten gepresenteerd en
besproken van twee onderzoeksprojecten. In deze projecten werden de effecten
van twee antidepressiva (resp. trazodone en citalopram) op de slaap bij depres-
sieven onderzocht . D e onderzoeksopzet was steeds dezelfde: een zogenaamd
'single blind design' met een week 'wash-out', een week placebo-behandeling,
een behandelperiode van vijf weken met het antidepressivum en tenslotte een
week met een placebo-behandeling. De resultaten van de slaapobservaties
waren gebaseerd enerzijds op polygrafische variabelen (Hoofdstukken 2 en 4)
en anderzijds op spectraalanalyse van het EEG tijdens de niet-REMS (Hoofd-
stukken 3 en 5).
In Hoofds tuk 2 werd het onderzoek naar de effecten van het antidepressivum
trazodone beschreven bij acht depressieve patienten. Eerder onderzoek door
anderen met dit antidepressivum liet geen onderdrukking van de REMS zien,
maar wel een toename van de langzame golven slaap [slow wave sleep (SWS);
een onderdeel van de niet-REMS]. In ons onderzoek vonden we echter wel een
significante onderdrukking van de REMS en geen significante verandering van de
SWS. Tevens werd een significante toename van de REMS-latentietijd vastgesteld.
Echter, er kon geen duidelijke samenhang gevonden worden tussen de verbete-
ring van de depressie en de veranderingen van de REMS.
In Hoofds tuk 3 werden de effecten van trazodone op de intensiteit in het
slaap-EEG tijdens de niet-REMS nagegaan. Tijdens de trazodone behandeling
werden er aanwijzingen gevonden voor een significante verlaging van de EEG-
energie in de 13 en 14 Hz frequenties en tijdens de onttrekking van het medica-
ment bleek de EEG-energie van de 1 Hz frequentie significant verlaagd te zijn.
De EEG-energie in de lagere frequenties was verminderd tijdens de trazodone
behandeling bij vier van de vijf patienten die verbeterden. Dit resultaat kan een
aanwijzing zijn dat de voorspelling dat een onderdrukking van de niet-REMS-
intensiteit een rol speelt bij het verbeteren van de depressie geldig zou kunnen
zijn.
In Hoofdstuk 4 werd het onderzoek beschreven naar de effecten van citalo-
pram op de slaap van zestien depressieven. Citalopram werkt zeer specifiek als
remmer van de heropname van het neurotransmitter serotonine in de hersenen.
In vergelijking met de mensen die relatief weinig verbeterden, bleken de men-
sen die relatief meer verbeterden aan te geven dat hun slaap en stemming verbe-
terden. Citalopram bemvloedde niet de slaap-continui'teit, maar veroorzaakte
een significante toename van het niet-REMS-2 stadium. Zowel direct na het
begin van de behandeling (na een dag medicatie) als aan het eind van de behan-
deling werd een significante verlaging van de hoeveelheid REMS vastgesteld.
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Hetzelfde gold voor een significante verlenging van de REMS-latentietijd. Maar
een samenhang tussen slaap-polygrafische variabelen en klinische verbetering
kon niet worden aangetoond.
In Hoofdstuk 5 werden de effecten van citalopram op de EEG-energie tijdens
de niet-REMS onderzocht. Aan het eind van de behandeling en na een week ont-
trekking van het antidepressivum werd een significante verlaging vastgesteld
van de EEG-energie van hoofdzakelijk de 8-9 Hz frequenties. Er kon geen dui-
delijke verandering gevonden worden van de EEG-energie in de deltafrequentie-
band (1-4 Hz), welke wordt beschouwd als de belangrijkste maat voor de niet-
REMS intensiteit. Een samenhang tussen de EEG-energie variabelen en de klini-
sche verbetering kon niet worden aangetoond.
In Hoofdstuk 6 werd een nabeschouwing van het onderzoek gepresenteerd.
Er werd in geconcludeerd dat de veronderstelling dat REMS-onderdrukking
rechtstreeks van belang is voor de verbetering van de depressie niet kon wor-
den bevestigd. Desalniettemin zou de onderdrukking van de REMS een voor-
waarde kunnen zijn voor het in werking treden van andere, nog onbekende,
processen die van belang zijn voor het herstel van de depressie.
Resultaten van fundamenteel slaaponderzoek op basis van het twee-proces-
senmodel van de slaapregulatie hadden aanleiding gegeven voor het spectraal-
analytisch onderzoek van dit proefschrift. Dit onderzoek heeft niet de bevin-
dingen opgeleverd die de hypothesen ondersteunen dat een onderdrukking van
de intensiteit van de niet-REMS van belang is voor de therapeutische werking
van antidepressiva. De resultaten maken evenwel duidelijk dat de huidige fun-
damentele kennis nog ontoereikend is om de rol van de slaapfysiologie bij het
herstel van de depressie tijdens een behandeling met antidepressiva vast te stel-
len.
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A P P E N D I X
Power spectra during non-REM sleep of each subject separately
treated with citalopram
Figures A to P show the power spectra during 91.5 min of non-REMS of each
subject separately during the acute phase (CIT-A), at the end of citalopram treat-
ment (CIT-E), and the withdrawal period (PW), relative to power spectra of base-
line (= 100 %). Power densities are plotted at the upper bounderies of the fre-
quency bins. The codes A to P of the figures correspond with those of the table
mentioned below. For symbols see Fig. A.
Table. Subject code, sex (F = female; M = male), age, HRSD baseline scores and change in HRSD sco-
res at the end of citalopram treatment, expressed as deviation from baseline. The rank order is
based on clinical response
Subject
code
A
B
C
D
E : .
F
G
H
I
J
K
L
M
N
O
P
Sex
M
F
M
M
M
M
F
F
M
F
F
F
M
M
M
F
Age
yrs
51
39
58
54
52
50
35
37
45
26
46
24
47
30
47
29
HRSD
baseline
score
26.0
32.0
28.0
28.5
24.0
29.0
32.0
24.0
22.0
24.0
30.0
23.5
31.0
24.0
22.0
21.0
HRSD
change
(%)
0
0
12
20
39
48
53
54
56
57
60
62
71
75
82
87
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CNS
EEG
EMG
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FFT
HRSD
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Non-REM
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REM
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Central Nervous System
Electroencephalography
Electromyography • ::
Electrooculography .
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Fast Fourier Transform
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COLOPHON
SLEEP, DEPRESSION AND ANTIDEPRESSANTS werd typografisch vormgegeven
door Ber Crouzen van Scorpio bv te Maastricht en onder zijn leiding gedrukt
in oktober 1993. De hier gebruikte letter is de Garamont Stempel.
Ontwerp omslag en afbeelding op frontispice naar een tekening P#/e Mrror,
1993, (29,5x22cm.), zijn van de hand van Ger Boosten, evenals de illustraties op
de hoofdstuktitels. (© Ger Boosten, Maastricht)
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